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Primary Sjögren’s syndrome is a systemic autoimmune disease primarily affecting salivary and 
lacrimal glands, but patients may also have other organ involvement. Development of Sjögren’s 
syndrome has been associated with genetic polymorphisms and aberrances in innate and adaptive 
immunity, which include abnormal B cell functions with autoantibody production, and increased 
activity of the interferon (IFN) system. Microbial triggers have been suspected to partake in the 
pathogenesis. The overall aim of this thesis was to characterize exogenous and endogenous 
mechanisms contributing to the immunopathology of Sjögren’s syndrome. 
Genetic variants associated with Sjögren’s syndrome convey low risk-increase for disease 
development, indicating that environmental factors must play an important role. However, at the 
start of the work leading up to this thesis, no environmental risk factors for Sjögren’s syndrome 
had been identified. Therefore, to assess the influence of smoking, we performed the largest 
questionnaire-based case-control study to date. We found that current and ever smoking was less 
frequent among patients compared to controls, however, smoking patterns were similar up until 
approximately 35 years before diagnosis and smoking thereafter declined in patients. We 
conclude that smoking does not appear to be a risk factor for development of Sjögren’s syndrome, 
but that early symptoms of dryness may influence behavior. Further, to define connections 
between previous infections and disease development, we extracted data on patients and matched 
controls from the Swedish National Patient Register. We found that a history of infection was 
associated with a higher risk of Sjögren’s syndrome, with overall stronger associations to anti-
Ro/SSA and anti-La/SSB positive disease. Infections of the respiratory tract associated both with 
autoantibody positive and negative disease, and a dose-response relationship was present in 
autoantibody positive patients. 
Previous studies have identified CXCR5 as a susceptibility locus for Sjögren’s syndrome. 
We describe a novel eQTL effect for CXCR5 in B cells. Further, decreased percentages of 
CXCR5+ cells with lower CXCR5 surface expression in the circulation coincided with higher 
CXCL13 plasma protein levels, and higher numbers of CXCR5+ cells were detected in salivary 
glands of patients compared to controls. We conclude that CXCR5+ cells likely relocate from the 
blood stream to the autoimmune target tissues in patients. By transcriptomic analysis of 
peripheral B cells, we found prominent type I and type II IFN signatures, as well as higher 
expression of chemokines and chemokine receptors in patients compared to controls, while 
inhibitors of cytokine signaling were downregulated. Our data add to the understanding of B cells 
in Sjögren’s syndrome and define potential candidates for future functional studies. 
Activation of the IFN system is often assessed by quantifying the expression of IFN 
regulated genes. However, RNA samples are not always available, wherefore alternative methods 
are needed. We describe two novel IFN scores calculated from protein levels in serum or plasma, 
and from levels of DNA methylation.  
Responses to microbial antigens can be studied in vivo during vaccination. We therefore 
assessed serological and cellular responses to influenza vaccination in patients with Sjögren’s 
syndrome and SLE. Untreated patients with Sjögren’s syndrome and SLE patients receiving no or 
light treatment responded to the viral antigens with higher vaccine-specific antibody titers 
compared to controls. Augmented antibody responses were associated with upregulated markers 
of type I IFN system activation at the mRNA level in monocytes and at the protein level in the 
circulation before vaccination. Specific components associated with a higher serological response 
were identified, which warrant further study. Our data increase the comprehension of immune 
reactions toward microbial antigens in autoimmune disease. 
In conclusion, this thesis expands our current understanding of environmental factors and 
immunopathogenic processes in primary Sjögren’s syndrome.  
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Autoimmune diseases are characterized by a loss of self-tolerance, which results in 
autoreactive immune cells and autoantibodies that may inflict tissue damage and cause 
inflammation. The importance of a detailed understanding of underlying immunopathogenic 
mechanisms in these diseases is evident though the implementation of biologics - 
predominantly monoclonal antibody-based drugs specifically targeting certain parts of the 
immune system. Moreover, measures to prevent autoimmune diseases rely on the 
identification of environmental risk factors that trigger or propagate disease. 
This thesis will focus on mechanisms involved in the autoimmune pathology of 
primary Sjögren’s syndrome, and to some extent systemic lupus erythematosus (SLE).  
1.1 THE IMMUNE SYSTEM 
The immune system has evolved to protect the body against harmful pathogens and to 
maintain homeostasis. It is commonly divided in two functional parts: innate immunity which 
provides fast but less specific protection, and adaptive immunity which acts slower in 
primary infections but can generate highly specific and effective responses. As implied by the 
name, innate immunity depends on inherited receptors for recognition of pathogens or other 
danger signals, whereas the adaptive immune system has the ability to generate specialized 
recognition receptors depending on which antigens that are encountered. Innate and adaptive 
immunity are highly interconnected through an intricate network of tissues, cells, and 
signaling molecules. Some aspects of the immune system of particular relevance for this 
thesis will be briefly reviewed below. 
1.1.1 Innate immunity 
Innate immunity constitutes a first-line defense and comprises barriers such as the skin and 
mucosal tissues as well as anti-microbial molecules therein, plasma proteins including the 
complement system, and cells in the circulation and in tissues. Innate immune cells have so 
called pattern recognition receptors (PRRs) which enable detection of microbial molecules 
and endogenous signs of damage, usually referred to as pathogen-associated molecular 
patterns (PAMPs) and damage-associated molecular patterns (DAMPs), respectively. Upon 
recognition of such patterns, cells of innate immunity may perform phagocytosis, kill infected 
cells, and/or promote inflammation and recruitment of adaptive immunity. The PRRs can be 
classified into five major families, of which the toll-like receptors (TLRs) are or special 
relevance for this thesis. Another important feature of the innate immune system is the ability 
to secrete anti-microbial interferons (IFN), which are implicated in several systemic 
autoimmune diseases. Whereas the involvement of adaptive immunity to autoimmune disease 
is obvious through autoreactive T and B cells, innate immunity also plays important roles, 
which I together with colleagues have reviewed in [1]. 
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1.1.1.1 Toll-like receptors 
Toll-like receptors are important PRRs which recognize a variety of conserved microbial 
components. The Toll protein was first described in Drosophila melanogaster where it was 
shown to play a role in embryonic development [2], but was later recognized also for its 
importance in protecting the flies against infections [3]. As of today, ten receptors (TLR1-10) 
have been described in humans, which are either present in the plasma membrane, or in 
endosomes (TLR3, 7-9) where they can recognize nucleic acids. Upon TLR ligation, 
downstream signaling results in activation of transcription factors, including members of the 
nuclear factor-kB (NF-kB) protein family, and the endosomal TLRs as well as TLR4 can 
induce production of type I IFNs.  
1.1.1.2 NF-kB signaling 
Nuclear factor-kB is a protein complex of intracellular transcription mediators which are of 
fundamental importance for inflammatory responses as well as for regulation of innate and 
adaptive immune processes.  
 
Figure 1. Schematic overview of classical NF-kB pathway signaling. 
 
Beyond induction of numerous inflammatory genes including those encoding cytokines 
and chemokines, the NF-kB family also regulates activation, differentiation and survival of 
immune cells [4]. The family consists of five proteins: RelA (p65), RelB, c-Rel, NF-kB1 
(p50), and NF-kB2 (p52), which form various homo- and hetero-dimers, but all exert their 
function by binding a sequence motif called kB enhancer [4]. Prior to activation, such protein 
dimers are found in the cytosol in a suppressed state. The suppression is mediated by a family 
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of inhibitors denoted Inhibitors of nuclear factor-kB (IkBs), with the most important member 
being IkBa. Simplified, classical activation of NF-kB is achieved through phosphorylation 
followed by ubiquitination and proteasomal degradation of IkBs by the IkB kinase (IKK). 
The IKK consists of a heterodimer of IKKa and IKKb and a regulatory protein called NF-kB 
essential modulator (NEMO). Upon degradation of the IkBs, the NF-kB protein dimers enter 
the nucleus to induce gene expression (Figure 1). 
1.1.1.3 The interferon system 
The anti-viral properties of IFNs have been known since their initial discovery in the 1950s 
[5, 6]. In humans, the IFN family consists of type I, II, and III IFNs, which are classified 
according to which receptor they bind. The type I IFNs are the largest class consisting of 12 
subtypes of IFN-a encoded by 13 genes, IFN-b, IFN-e, IFN-k, and IFN-w. All type I IFNs 
bind and signal through the ubiquitously expressed interferon-a/b receptor (IFNAR) which is 
a heterodimer of the subunits IFNAR1 and IFNAR2 [7]. Upon binding, the receptor subunits 
dimerize leading to activation of Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2), 
which, in canonical type I IFN signaling, causes receptor phosphorylation and recruitment 
and phosphorylation of signal transducer and activator of transcription (STAT) proteins 
(Figure 2). Simplified, heterodimers of phosphorylated STAT1 and STAT2 form a complex 
with IFN regulatory factor (IRF)9 denoted interferon-stimulated gene factor 3 (ISGF3) which 
binds and induces expression at IFN-stimulated response elements (ISRE) sites (Figure 2). 
However, signaling via other combinations of STATs as well as signaling not mediated via 
the JAK-STAT pathway also occurs [8]. 
 




Type II IFN consists solely of IFN-g which has modest anti-viral activity but is 
important for activation of macrophages and for governing differentiation of T cells [9]. The 
type III IFNs are the most recently described and least studied group consisting of IFN-l1 
(IL29), IFN-l2 (IL28A) and IFN-l3 (IL28B). Type III IFNs elicit responses similar to type I 
IFNs, but signal through another receptor with more limited tissue expression, primarily on 
epithelial cells [10]. 
1.1.2 Adaptive immunity 
Adaptive immunity is phylogenetically younger and more complex compared to innate 
immunity. T and B cells are central to the functions of adaptive immunity and both carry 
epitope-specific receptors denoted T and B cell receptors, respectively. Each cell carries 
receptors recognizing only one antigen, which had been hypothesized in Burnet’s clonal 
selection theory more than 80 years ago [11]. The B cell receptor constitutes a membrane-
bound immunoglobulin which may be secreted as antibodies, whereas the T cell receptor is 
always membrane bound. B cell receptors can recognize various types of molecules, whereas 
T cell receptors will only recognize peptide antigens displayed by major histocompatibility 
complex (MHC) I or MHC II molecules. In contrast to the germline encoded receptors of 
innate immunity, cells of the adaptive immune system have the capacity to modify their 
receptors through DNA rearrangements [12]. An astonishing variety of receptor specificities 
is achieved through stochastic rearrangement of various V, D and J segments in the 
immunoglobulin and T cell receptor genes. B cells can further adapt and perfect their 
receptors through isotype switching, somatic hypermutation, and affinity maturation by 
interaction with T cells in peripheral lymphoid organs. 
The chemokine receptors CXCR5 and CCR7 promote migration of T and B cells into 
peripheral lymphoid organs in which some cells participate in the formation of germinal 
centers (GCs), where high-affinity antibody-secreting cells are generated from B cells with 
the help of specialized follicular dendritic cells (FDCs) and T follicular helper cells (Tfh). B 
cells achieving the highest affinity will then differentiate into memory B cells and long-lived 
plasma cells, whereby an immunological memory is generated. 
1.1.2.1 Tolerance 
In a healthy state, adaptive immunity thus harbors the ability to target virtually any antigens 
that may pose a danger, but simultaneously retains the ability to avoid attacking antigens 
from the own body. This discrimination between self and non-self is denoted immune 
tolerance and errors during this process may result in autoimmune disease.  
 During the 1940s and 50s, it became evident that immune tolerance must be 
established during early life. It had been observed that dizygotic twin cattle sharing a 
common circulation through the placenta became tolerant of the other twin’s blood cells later 
in life [13]. Further, experiments in mice showed that inoculation of cells from another donor 
during fetal life made the recipient tolerant to skin grafts from the donor even during adult 
life [14]. These observations eventually led to the hypothesis that self-reactive lymphocytes 
are removed during maturation [11], termed clonal deletion. 
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Immune tolerance is broadly divided into central and peripheral tolerance mechanisms. 
Central tolerance mechanisms refer to negative selection of T and B cells in cases where 
somatic recombination has resulted in high receptor affinity for antigens presented in the 
thymus or bone marrow, and also to the generation of immunosuppressive regulatory T cells 
(Tregs). Nevertheless, B cells that recognize self-epitopes may undergo an additional process 
named receptor editing to become non-self-reactive B cells. During maturation in the thymus, 
T cell are presented with self-antigens from all tissues of the body by virtue of the 
transcription factor AIRE, which promotes the expression of proteins not otherwise expressed 
in the thymus [15]. Mutations in the AIRE gene cause the autoimmune condition autoimmune 
polyendocrinopathy syndrome type 1 (APS-1) in humans [16, 17], further underlining the 
importance of this gene during tolerogenic processes. 
Autoreactive lymphocytes may however escape central tolerance mechanisms whereby 
peripheral tolerance mechanisms can act to prevent damage. Such mechanisms include 
immune suppression by Tregs, cell death or anergy by antigen recognition without co-
stimulation, or by expression of death receptors such as Fas and Fas ligand. The forkhead box 
P3 (FOXP3) gene is essential for development and function of Tregs, and mutations in this 
gene results in the autoimmune immunodysregulation polyendocrinopathy enteropathy X-
linked (IPEX) syndrome [18]. Furthermore, inhibitory T cell receptors such as programmed 
cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are 
also important for peripheral tolerance mechanisms. Indeed, monoclonal antibodies targeted 
at these receptors, which have been developed for treatment of cancers, may, as an adverse 
effect, induce autoimmune reactions in humans [19].  
In all, numerous mechanisms orchestrate a delicate balance between protective 
immunity and self-tolerance, in which failure of tolerogenic mechanisms may result in 
development of autoimmune disease.  
1.2 AUTOIMMUNE DISEASE 
Autoimmune disease thus results from an erroneous targeting of the immune system against 
healthy tissue. The concept of autoimmunity was first established in 1900 by immunologist 
Paul Ehrlich who coined the term “horror autotoxicus” to describe the unwillingness of the 
immune system to target the own body [20]. Ehrlich postulated that autoimmunity was not 
possible, and due to his substantial influence in the field of immunology the existence of such 
diseases remained controversial for a long time. Starting in the 1950s, a modern 
understanding of autoimmunity and autoantibodies formed [21]. Whereas there is still 
disagreement regarding which diagnoses that meet the criteria to be classified as an 
autoimmune disease, community prevalence has been estimated at around 4.5 to 9.4% [22, 
23]. Apart from the significant morbidity associated with the diseases, much-increased 
mortality rates are observed [24, 25]. Data on the overall cost of the burden of autoimmune 
disease are scarce, but due to the chronic nature of the diseases and a high prevalence of co-
morbidities the societal costs are undoubtedly substantial. 
Although great advances have been made regarding treatment, autoimmune diseases 
generally cannot be cured. Traditionally, corticosteroids in combination with disease-
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modifying anti-rheumatic drugs (DMARDs) or other immunosuppressive drugs have been 
used to control disease activity. In more recent years, biological therapies or “biologics”, have 
been added to the therapeutic arsenal, often showing very good efficacy and tolerability [26]. 
Other proposed novel therapeutic approaches include epitope-specific vaccination and the use 
of chimeric autoantibody receptor (CAAR) T cells [27, 28]. The success of biologics 
exemplifies and underlines the importance of detailed research on dysregulated 
immunological pathways to enable development of novel therapeutic approaches.  
The precise nature of why autoimmune diseases occur is not known, yet it is clear that a 
combination of genetic and environmental factors is involved in their onset. Several studies 
have also determined significant gene-environment interactions, through which presence of 
one factor may influence the effect of another [29, 30]. 
1.2.1 Genetic factors in autoimmune disease 
Genetic factors conferring increased susceptibility to autoimmune disease are evident through 
higher disease concordance rates between monozygotic twins compared to dizygotic twins or 
other siblings, with concordance rates of approximately 12-15% for monozygotic and 3-8% 
for dizygotic twins [31-33]. In the case of Sjögren’s syndrome, a few case reports exist on 
twins concordant for the disease, but large twin studies are missing. Nevertheless, familial 
aggregation of the disease has been confirmed [34]. Given the shared immunopathological 
characteristics of several autoimmune diseases, such as those between Sjögren’s syndrome 
and SLE, a familial clustering of various autoimmune diseases could be expected, and such 
observations are amply documented in the literature [35]. Consistently, variants in many 
genes or genetic loci have been associated with several autoimmune diseases. 
1.2.1.1 Genetic variants associated with autoimmune disease 
Monogenic variations or mutations that directly result in autoimmune diseases are very rare 
and often associate with severe disease phenotypes. Interestingly, by studying such 
monogenic diseases, pathways important for immune homeostasis have been pinpointed, as 
exemplified by studies of the IPEX syndrome and the FOXP3 gene [18, 36]. Another 
example of a monogenic cause of autoimmunity is deficiency of the complement protein 
C1q, which is the strongest risk factor for SLE with a penetrance of nearly 100% in both 
sexes [37]. 
Genome-wide association studies (GWAS) have pinpointed common genetic variants 
which associate with increased or decreased risk of autoimmune diseases in a multitude of 
loci. However, these variants, usually single nucleotide polymorphisms (SNPs), only convey 
modest effects. Some genetic variants have, as mentioned above, been found to confer 
increased risk of several autoimmune diseases, thus implying shared immunopathological 
pathways [38]. A prime example is the human leukocyte antigen (HLA) region on 
chromosome 6, where the strongest genetic associations are found. However, extensive 
linkage disequilibrium among HLA alleles and vast genetic variability in the locus has 
hampered precise understanding of these associations. 
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Hundreds of non-HLA risk loci have also been identified, out of which many are 
important in immune responses such as T cell signaling and differentiation, immune cell 
activation, innate immunity, and TNF signaling [39]. Specifically, genes in which 
polymorphisms associate with multiple systemic autoimmune diseases include e.g., STAT4, 
IRF5, PTPN22 and FAM167A-BLK [40, 41].  
1.2.2 Environmental factors in autoimmune disease 
The observation that concordance rates of autoimmune diseases in monozygotic twins are 
rather low [31-33, 42] and that heritability estimates are far from 100% [43] highlights the 
fact that genetics alone does not fully explain the development of autoimmune diseases. 
Consequently, environmental factors must play an important role. Indeed, for several 
autoimmune diseases, there is strong epidemiological evidence of associations between 
environmental factors and disease development, including exposure to smoking, silica, and 
solvents [44]. Moreover, reports of individuals developing autoimmune-like disease upon 
exposure to pharmaceutical drugs including IFN-a, antifungals, and angiotensin converting 
enzyme inhibitors [45-47] further support that exogenous agents can have a causative effect.  
1.2.2.1 Identified and suggested environmental risk factors 
In a comprehensive review, an expert panel assembled by the National Insitute of 
Environmental Health Sciences evaluated the evidence for the importance of various 
environmental factors in the development of autoimmune diseases [44]. The panel expressed 
confidence that silica exposure is a risk factor for development of several autoimmune 
diseases, that smoking is a risk factor for development of seropositive rheumatoid arthritis 
(RA), that solvent exposure is a risk factor for development of systemic sclerosis, and that 
ultraviolet radiation exposure is a protective factor for multiple sclerosis (MS). However, 
many other risk factors have been linked to development of autoimmune diseases, with 
varying degree of certainty. Specifically, smoking has also been associated with development 
of MS [48-50], SLE [51, 52], anti-Jo-1 antibodies in myositis [53], and, as mentioned above, 
seropositive RA [54]. Interestingly, gene-environment interactions have been determined 
between HLA alleles and smoking in RA [29] and MS [48], in which smokers carrying a risk 
genotype have much-increased odds ratios (ORs) compared to non-smokers without risk 
genes. Further, silica exposure has been reported to increase the risk of developing f RA [55], 
SLE [56], and systemic sclerosis [57]. Other noteworthy associations between environmental 
factors and disease development include low vitamin D and adolescent obesity with 
development of MS [58], sunlight exposure with flare of SLE [59, 60], and exposure to 
textile dust with development of RA [61]. 
Infections have long been suggested as risk factors for development of autoimmune 
diseases. For instance, a role of Epstein-Barr virus (EBV) infection has been suggested in MS 
[58], RA [62], SLE [63, 64], and Sjögren’s syndrome [65]. Mechanisms by which viral 
infections may induce autoimmunity, and different viruses implicated in autoimmune 
diseases including Sjögren’s syndrome have been reviewed by myself together with 
colleagues [66] and others [67] elsewhere. 
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Exposure to various environmental factors may be of different importance during 
certain timeframes in the autoimmune process and will interact with genetic risk factors 
carried by the individual, as depicted for Sjögren’s syndrome below (Figure 3). 
 
 
Figure 3. Suggested model of the contribution of environmental factors in the 
autoimmune process of autoantibody positive Sjögren’s syndrome. (a) The disease 
progression of a genetically susceptible individual is indicated by the green line. Various 
environmental factors (A-C) contribute risk or protection during different stages of the 
disease process. Certain factors may be important e.g., for triggering serological 
autoimmunity while other, or the same, factors may influence disease severity. (b) 
Different environmental factors are likely to interact both with underlying genetics, as 
well as with each other. Reprinted with permission from [66]. 
 
1.3 SJÖGREN’S SYNDROME 
Primary Sjögren’s syndrome is a systemic autoimmune disease characterized by 
hypofunction of exocrine glands, principally the salivary and lacrimal glands, resulting in the 
cardinal symptoms of dryness of eyes and mouth, which are commonly referred to as sicca 
symptoms. The disease is often termed primary when occurring isolated, and secondary when 
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occurring in the presence of another systemic autoimmune disease. This thesis is based on 
studies of the primary form of the disease and no patients with secondary Sjögren’s syndrome 
have been included. Therefore, for the purpose of conciseness, the term Sjögren’s syndrome 
is used in this thesis and refers to the primary form of the disease.  
The prevalence of Sjögren's syndrome has been estimated at about 0.05-0.21% [68-70], 
and a substantial gender bias is observed with a female to male ratio of at least 10 to 1 [71, 
72]. The incidence peaks around 40-50 years of age, however, there is usually a considerable 
delay between symptom onset and diagnosis. In addition to the oral and ocular dryness, 
patients may also experience symptoms such as fatigue, arthralgia, xeroderma, low-grade 
fever, and symptoms of exocrine dysfunction of mucosal surfaces in the oropharynx, bronchi, 
gastrointestinal tract, and in women, the vagina. Approximately 30 to 40% of patients 
develop a more systemic phenotype with organ-specific extra glandular manifestations 
(EGMs) that may involve e.g., arthritis, synovitis, cutaneous vasculitis, polyneuropathy, 
interstitial lung disease, and tubulointerstitial nephritis.  
The morbidity associated with Sjögren’s syndrome should not be underestimated, and 
overall mortality rates are increased [73]. Common symptoms such as fatigue, sicca 
symptoms, and arthralgia can have considerable impact at the individual level and may cause 
inability to work and decreased social interactions. In fact, patients with Sjögren’s syndrome 
report a reduction in quality of life and health-related quality of life at levels comparable to 
patients with RA and SLE [74], and one study found even higher rates of psychological 
distress compared to patients with SLE [75]. 
1.3.1 Autoantibodies 
Several types of autoantibodies can be found in the circulation of patients with Sjögren’s 
syndrome and autoantibodies against Sjögren’s-syndrome-related antigen A (Ro/SSA) and 
Sjögren’s-syndrome-related antigen B (La/SSB) are detected in approximately 70% and 50% 
of patients, respectively [76]. Intriguingly, disease-associated autoantibodies have been 
observed in sera collected as early as two decades before diagnosis [77, 78], indicating that 
humoral autoimmunity may be initiated many years prior to clinically overt disease (Figure 
3). Detection of anti-Ro/SSA and anti-La/SSB autoantibodies is associated with earlier 
disease onset, more severe disease with higher prevalence of EGMs, and correlate with 
various laboratory features such as leukopenia, thrombocytopenia, hypergammaglobulinemia, 
and higher expression of IFN stimulated genes (ISGs) [79-81]. Notably, stratification of 
patients by anti-Ro/SSA and/or anti-La/SSB positivity reveals genetic differences between 
autoantibody-positive and autoantibody-negative patients, and in fact, the HLA associations 
are exclusive to patients positive for these autoantibodies [82, 83]. 
1.3.2 Classification criteria 
Classification criteria have been developed in order to standardize diagnosis for patients 
taking part in research studies, but these criteria are also widely used by physicians for 
establishing diagnosis in the clinical setting. Over the years, numerous sets of criteria have 
been proposed for classification and/or diagnosis of Sjögren’s syndrome and between 1965 
and 2002 no less than eleven such criteria were published [84]. However, until 2002 no 
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criteria had been endorsed by the American College of Rheumatology (ACR) or the 
European League Against Rheumatism (EULAR) [85]. The first set of classification criteria 
to be accepted by these organizations were the 2002 American-European Consensus Group 
(AECG) criteria [86], which are the criteria employed for classification of patients in the 
studies of this thesis. A new set of classification criteria were endorsed by the ACR in 2012 
[87] but never reached wide usage, mainly since the older criteria performed well, robust 
validation was lacking, and also because of a lack of resources to perform the required ocular 
staining score. The latest classification criteria are the 2016 ACR/EULAR classification 
criteria [85], which are similar to, and have a high level of concordance with the AECG 
criteria [85, 88].  
The 2002 AECG and the 2016 ACR/EULAR criteria are much alike in the sense that 
key elements of both comprise objective proof of ocular and salivary gland involvement, 
minor salivary gland biopsy, and presence of Sjögren’s syndrome-associated autoantibodies. 
In both sets of criteria, signs of inflammation in minor salivary gland biopsies are a 
prerequisite for diagnosis for individuals where Sjögren’s syndrome-associated 
autoantibodies are not detected in serum. In contrast to the 2002 AECG criteria, the 2016 
ACR/EULAR criteria use a weighted scoring system. Moreover, the questionnaire for 
glandular symptoms included as part of the 2002 AEGC criteria has been changed to be used 
as inclusion criteria before applying the 2016 ACR/EULAR criteria. One important 
difference comparing the 2016 ACR/EULAR and the 2002 AECG criteria is that individuals 
who are anti-La/SSB positive but anti-Ro/SSA negative will no longer be classified as 
Sjögren’s syndrome unless they have a positive biopsy. The decision to not include anti-
La/SSB autoantibodies as part of the new criteria was based on results from statistical 
analyses showing that exclusion of this parameter did not affect classification performance 
[85]. Also contributing to the exclusion of anti-La/SSB were expert group discussions and a 
study by Baer et al. showing that serological presence of anti-La/SSB without anti-Ro/SSA is 
not significantly associated with Sjögren’s syndrome phenotypic features [89]. 
1.3.3 Disease activity index 
Monitoring of disease activity in clinical studies is commonly performed using the EULAR 
Sjögren’s Syndrome Disease Activity Index (ESSDAI) [90] and the patient-reported scoring 
index EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) [91]. In the ESSDAI, 
scores from twelve organ-specific domains are weighted into a final index. A criticism of the 
index has been that the many patients who only present with sicca symptoms score very low 
on this index and therefore cannot be adequately monitored, while patients with systemic 
manifestations and several EGMs may score very high, since the index score ranges from 0 to 
123. The ESSPRI score is used as a complement to the ESSDAI, and it is calculated as the 
mean of three subjective symptom scales graded 1-10: dryness, fatigue, and pain. Correlation 
between the two scores is poor [92, 93], indicating that the ESSDAI and ESSPRI scores are 
complementary and should be evaluated separately [93]. 
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1.3.4 Genetic factors  
Several candidate gene studies, as well as two large association studies, have identified 
associations between genetic variants and risk for development of Sjögren’s syndrome [41, 
94, 95]. One study in Caucasians revealed genome-wide significant associations with the 
HLA region as well as the STAT4, IL12A, TNIP1, IRF5, BLK-FAM167A, and CXCR5 loci 
[94]. The associated genes are important in processes such as antigen presentation, 
lymphocyte signaling, the NF-kB pathway, and the IFN signaling pathway [41]. 
1.3.5 Environmental factors 
Environmental risk factors for development of Sjögren’s syndrome have been little 
investigated. Although a link to various viral infections has been repeatedly suggested, 
convincing data support this hypothesis are lacking. Myself together with colleagues have 
previously reviewed environmental factors that may be of importance in the pathology of 
Sjögren’s syndrome [66]. In summary, studies on exposures prior to diagnosis have indicated 
possible associations between Sjögren’s syndrome and exposure to infections in general, 
nontuberculous mycobacterial infection, helicobacter pylori infection, low lifetime exposure 
to estrogen, deficiency of vitamin D, stress, former smoking, and silicone breast implants 
[66]. Importantly, however, although several studies have indicated association with 
infections in general, all potential risk factors need further study and thus far no single 
environmental risk factor for Sjögren’s syndrome has been unambiguously identified. 
1.3.6 The immunopathology of Sjögren’s syndrome 
Sjögren’s syndrome shares several common features with other systemic autoimmune 
diseases such as production of autoantibodies, formation of ectopic lymphoid structures, high 
levels of several pro-inflammatory cytokines, and activation of the IFN system. Thus, the 
immunopathogenesis involves both innate and adaptive immunity. Specifically, aberrances in 
B cell function and persistent production of type I IFN have emerged as two central features.  
1.3.6.1 Immune cell aberrations 
Several aspects of the disease imply chronic activation of B cells, a feature that remains 
incompletely understood. Patients display disturbed peripheral B cell subpopulation 
frequencies with more naïve B cells and fewer CD27+ memory B cells compared to controls 
[96, 97]. Consequences of the B cell overactivity include hypergammaglobulinemia and 
production of autoantibodies toward the ribonucleoproteins SSA (Ro52 and Ro60) and SSB 
(La). Interestingly, autoantibody production partly occurs locally in inflamed salivary glands 
[98], where the Ro52 autoantigen has been shown to be present [99] and higher local 
autoantibody production is observed in patient salivary glands containing GC-like structures 
[100]. Such structures are observed in salivary glands from 30-40% of patients [101], and 
their presence is associated with an increased risk of development of B cell lymphomas [102, 
103]. Of note, genetic variation close to the gene locus of the chemokine receptor CXCR5 
locus has been linked to Sjögren’s syndrome [94], and intriguingly, CXCR5 and its ligand 
CXCL13 are central in the formation and organization of GC-like structures [104, 105]. 
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Overall, several lines of evidence point to the importance of B cells and GC-like structures in 
the pathology of Sjögren’s syndrome.  
T cells, predominantly CD4+, are the major infiltrating cell type the salivary glands at 
early stages of the disease [106], and strong genetic association between Sjögren’s syndrome 
and the HLA locus [94] further highlights their importance. T cell polarization toward Th1 
and Th17 phenotypes is believed to contribute to the inflammation and disease [107, 108]. 
Salivary gland epithelial cells (SGEC) may actively contribute to propagation of the 
disease through expression of co-stimulatory molecules such as CD86 [109] and release of 
inflammatory molecules such as B cell activating factor (BAFF) and CXCL13 [108, 110]. 
Moreover, increased apoptosis of SGECs could be an important cause of sustained 
autoantigen exposure [111]. 
 
Figure 4. Schematic illustration of proposed mechanisms underlying Sjögren’s syndrome. Infections 
disrupt the salivary gland epithelium causing an inflammatory microenvironment with production of 
type I IFN and release of autoantigens and microbial antigens from dying cells. Subsequently, 
microbial and self-antigens are processed and presented, whereby autoreactive B and T cells are 
activated, in turn causing B cell differentiation into autoantibody producing plasma cells. The 
autoantibodies form immune complexes with autoantigens, which are endocytosed by pDCs, causing 
further production of type I IFNs. In turn, the type I IFNs promote differentiation and activation of 
autoreactive B cells thus causing increased autoantibody production. Hereby, a self-sustaining cycle of 
autoimmunity is created. (pDCs, plasmacytoid dendritic cells; TCR, T cell receptor; IFN, interferon; 
MHC, major histocompatibility complex). Reprinted with permission from [66]. 
 
1.3.6.2 Disturbed signaling pathways 
A wide set of inflammatory cytokines and chemokines are expressed at high levels in 
Sjögren’s syndrome, including type I IFNs which are often thought of as key pathogenic 
mediators (Figure 4). After initial reports of increased type I IFN activity and accumulation 
of IFN-producing plasmacytoid dendritic cells (pDC) in salivary glands of patients [112, 
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113], augmented activity of the type I IFN system was also reported systemically in 
peripheral blood cells [114]. A so called “IFN signature” is present in about 55% of patients 
and presence of the signature correlates with disease activity, higher titers of anti-Ro/SSA 
and/or anti-La/SSB autoantibodies, and hypergammaglobulinemia [115]. Therefore, patient 
stratification based on the presence of the signature has been suggested. The fact that genetic 
variants in the STAT4 and IRF5 loci have been associated with Sjögren’s syndrome further 
implies the importance of type I IFN pathways in the disease [94, 116]. Because of the anti-
microbial properties of type I IFNs, it has been suspected that infections may act as initiators 
of their uncontrolled signaling (Figure 4). 
Plasmacytoid dendritic cells have been identified as main producers of type I IFN and 
are often considered to be of central importance in the pathogenesis of Sjögren’s syndrome. It 
has been proposed that presence of autoantibodies results in RNA-containing immune 
complexes which stimulate IFN production by pDCs [112]. The secreted type I IFNs in turn 
stimulate other cells of the immune system and lead to increased inflammatory cytokine 
production. Specifically, type I IFN can induce the production of BAFF via IRF1 and IRF2 
[117], and BAFF in turn promotes autoantibody production in B cells [118, 119]. Hereby, a 
vicious and self-propagating cycle of immune activation is established (Figure 4) [120]. 
The importance of BAFF in the pathology of Sjögren’s syndrome is well established 
[121] and levels of BAFF in serum have been shown to correlate with ESSDAI scores [122]. 
Interestingly, transgenic mice overexpressing BAFF develop Sjögren’s syndrome-like 
pathology with age [123], and overexpression of BAFF in a Sjögren’s syndrome mouse 
model was shown to result in enhanced lymphocytic infiltration, and B cell activation and 
differentiation in the target tissue [124]. 
1.3.7 Treatment 
To this day, no immunomodulatory treatments have been proven efficacious for treatment of 
Sjögren’s syndrome. While muscarinic agonists have been shown to be beneficial for treating 
oral and, to some extent, ocular dryness [125], these drugs are associated with side effect 
which limit their use. Therefore, treatment is focused on relieving symptoms related to 
dryness by using topical agents such as moisture replacements for eyes and mouth, and local 
estrogen treatment to relieve dryness of the vagina.  
Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of several 
rheumatic diseases. In SLE, HCQ has been shown to reduce the number and severity of 
clinical flares, and to improve overall survival [126]. Although HCQ is sometimes used for 
treatment of Sjögren’s syndrome, the only randomized clinical trial conducted to date could 
not determine efficacy of the drug after 24 weeks of treatment [127]. However, a small 
randomized controlled clinical trial of leflunomide-HCQ combination therapy indicated 
significant reduction of ESSDAI scores at 24 weeks, but this recent trial was small and this 
combination of the drugs needs to be studied further [128]. 
Several trials of biological drugs have been conducted. Randomized controlled trials of 
anti-TNF treatment have not been successful [129, 130], likewise, a recent trial of abatacept 
(blocking of CD28-CD80/CD86 co-stimulation) failed to reach the primary outcome [131]. 
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However, a recent proof-of-concept study of iscalimab (anti-CD40 blocking the 
CD40/CD40L pathway) showed preliminary efficacy, with significant reduction in ESSDAI 
score after 12 weeks of treatment compared to placebo [132], thus warranting further studies.  
In line with the central role of B cells in the pathogenesis of Sjögren’s syndrome, 
therapies aimed at B cell abrogation have been assessed. Although treatment with rituximab 
(anti-CD20 mediated B cell depletion) has been shown to decrease the number of B cells, 
GCs, and lymphoepithelial lesions in parotid gland biopsies [133], randomized clinical trials 
failed to reach their primary endpoints [134, 135]. Further, an open-label phase II study 
investigated the effect of belimumab (BAFF inhibition), in which 60% of the treated patients 
reached the primary endpoint, indicating a possible efficacy [136]. Recently, potential 
efficacy of ianalumab (B cell-depleting, BAFF receptor-blocking) was indicated in a phase 
IIb study [137]. 
Difficulties in finding efficacious drugs for treatment of Sjögren’s syndrome partly 
relate to heterogeneity of the disease, and to challenges in finding accurate measurements of 
disease activity.  
1.3.8 Comorbidities and complications 
An important complication associated with Sjögren’s syndrome is development of 
lymphoma, most commonly low-grade non-Hodgkin lymphoma, with a lifetime risk of 
approximately 5% [103, 138]. Predictors of lymphoma development include lymphopenia, 
low complement protein levels, cryoglobulinemia, monoclonal component in serum or urine, 
permanent swelling of salivary glands, splenomegaly and lymphadenopathy, and palpable 
purpura [139].  
Patients are also at increased risk of developing cardiovascular disease, with an 
especially pronounced risk in those positive for anti-Ro/SSA and anti-La/SSB autoantibodies 
[140]. Moreover, presence of the anti-Ro/La autoantibodies in pregnant women can result in 
development of neonatal lupus syndrome in the child, which may include the rare 
complication congenital heart block [141]. 
1.4 SYSTEMIC LUPUS ERYTHEMATOSUS 
Systemic lupus erythematosus is a heterogeneous disease characterized by multi-organ 
involvement and production of a vast set autoantibodies. In the 1950s, the 5-year survival rate 
was estimated to be less than 50% [142], but this figure has dramatically increased to more 
than 95% [143], partly owing to earlier diagnosis, better understanding of the disease, and 
new therapeutic regimens. The disease predominantly affects women of fertile age but can 
occur at any age in both sexes. There is a considerable variance in the reported prevalence 
and incidence across the world [144]. In Sweden, the estimated prevalence of SLE is 65/100 
000 with an annual incidence of about 2.8-5/100 000 [145, 146].  
The diagnosis can be established in the presence of disease manifestations from more 
than one organ system and at least one characteristic autoantibody. Classification criteria 
originally developed for research studies are often used to support the diagnosis, and the most 
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commonly used are the 1982 ACR criteria where at least 4 out of 11 criteria need to be 
fulfilled for classification as SLE [147]. Disease activity in clinical studies is typically 
monitored using the SLE Disease Activity Index (SLEDAI) [148]. 
Large numbers of genetic association studies have revealed more than 100 loci 
associated with SLE, but each locus usually with a small effect on risk [149]. Interestingly, 
some genetic variations have been linked to specific organ manifestations or comorbidities. 
Variation in STAT4 has been associated with production of dsDNA-autoantibodies, severe 
renal insufficiency, and stroke [150-152]. Likewise, genetic variation in IRF8 has been 
associated with coronary heart disease [153]. Suggested or confirmed environmental risk 
factors include ultraviolet radiation, smoking, exposure to silica, and infections [44].  
The immunopathology of SLE shares many features with that of Sjögren’s syndrome, 
including augmented activity of B cells and the type I IFN system. However, SLE is also 
characterized by high amounts of exposed autoantigens, which is reflected by the fact that 
more than 100 autoantibodies have been described [154]. Two major causes of high 
abundance of autoantigens in SLE is the inability to clear debris from dead cells, and 
impaired degradation of neutrophil extracellular traps [155, 156]. Improperly cleared immune 
complexes containing nucleic acids are internalized by pDCs via FcgRIIa, whereupon the 
nucleic acids interact with TLR7 and TLR9 in endosomes and stimulate production of type I 
IFN [157, 158]. The central importance of type I IFN in the pathogenesis of SLE is supported 
by observations of development of SLE, or symptoms associated with SLE, in individuals 
treated with IFN-a [45, 159].  
Treatment of SLE depends on the type of organ involvement and severity of the flare. 
The antimalarial drug HCQ is known to prevent flares and prolong life and is therefore 
recommended to all patients if there are no contraindications. Antimalarial agents are 
otherwise used especially for skin and joint involvement. Systemic corticoids are effective in 
relieving symptoms and decreasing inflammation. Immunosuppressive drugs such as 
methotrexate, azathioprine, cyclosporine, and mycophenolate mofetil are also used. 
Regarding biological treatment, several drugs are used off-label. Thus far, the BAFF-
inhibiting drug belimumab is the only officially approved biological agent for treatment of 
SLE. However, anifrolumab, a monoclonal antibody targeting IFNAR1 was recently shown 
to be efficacious in patients with SLE [160], which will be discussed later in this thesis. 
1.5 VACCINATION IN RHEUMATIC DISEASES 
Prevention of infectious diseases through vaccination undoubtedly represents one of the 
greatest accomplishments throughout the history of medicine. Importantly, patients with 
rheumatic diseases are at increased risk of infection [161, 162] and a study by Brito-Zerón et 
al. identified infections as the second most common cause of death, after cardiovascular 
disease, in patients with Sjögren’s syndrome [73]. Consequently, there is an undisputable 
need to protect patients with rheumatic diseases against infections. 
Large, randomized studies assessing efficacy and safety of vaccinations in patients with 
rheumatic diseases are lacking. Also, vaccine efficacy is often estimated by measuring 
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serological responses i.e., titers of neutralizing antibodies, which do not always correspond 
well to clinical protection. Because of variations in study design, type of included patients, 
differences in treatments, and differences in vaccines used, many studies show conflicting 
results regarding vaccine efficacy, and thus, firm conclusions are generally difficult to make. 
The efficacy of various vaccines in patients with different rheumatic diseases and different 
treatments has been extensively reviewed elsewhere [163-165]. Briefly, most vaccines seem 
to be effective in patients with rheumatic diseases, but for some vaccines and for some 
treatment groups the response to vaccination is lower in patients compared to controls. 
Vaccination against H1N1 influenza in patients with SLE, RA, ankylosing spondylitis, 
psoriatic arthritis, and dermatomyositis is one such example, in which these patient groups 
have significantly reduced seroprotection rates compared to healthy controls [166-168]. B 
cell-depleting treatment using rituximab is the therapy most consistently associated with poor 
responses to vaccinations [163, 164], and consequently, the 2019 EULAR recommendations 
state that vaccines ideally should be administered before start of such therapy [169].
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2 AIMS OF THE THESIS 
Autoimmune diseases are thought to occur through combinations of genetic and 
environmental risk factors. Although primary Sjögren’s syndrome is one of the most 
prevalent rheumatic diseases, much remains unknown about its etiology and 
immunopathogenesis. The aims for the work performed in this thesis were to identify specific 
environmental factors of importance for development of Sjögren’s syndrome and to improve 
understanding of dysregulated immune processes of adaptive and innate immunity, with a 
focus on in vivo immune responses to microbial antigens. 
The specific aims of the thesis were: 
- To perform epidemiological studies using questionnaires and the Swedish health care 
registers for identification of environmental factors of importance for development of 
Sjögren’s syndrome 
 
- To identify and describe differences in immune activation in vivo after microbial 
antigen exposure comparing patients with systemic autoimmune disease and controls 
 
- To establish novel methods for quantification of IFN system activation, which do not 
rely on RNA samples 
 
- To define cellular immune dysregulation in Sjögren’s syndrome by obtaining an in-
depth understanding of differential B cell gene expression patterns and by exploring 






3 METHODOLOGICAL CONSIDERATIONS 
In the following section, select methods included in this thesis are discussed with a focus on 
limitations and advantages. Detailed descriptions of each method are available in the 
individual papers. 
3.1 STUDY POPULATIONS 
All papers included in this thesis include data or biological samples collected from patients 
with Sjögren’s syndrome or SLE, and from controls. To ensure correctly classified patients 
and avoid errors which, for instance, may occur when selecting patients based on ICD codes, 
we chose to include only patients with Sjögren’s syndrome fulfilling the 2002 AECG criteria 
[86] and patients with SLE fulfilling the revised 1982 ACR criteria for SLE [147], which had 
been evaluated by a rheumatologist seeing the patient. However, new classification criteria 
for Sjögren’s syndrome were published during the work leading up to this thesis [85]. While 
the new criteria do not consider isolated anti-La/SSB autoantibodies as a marker of Sjögren’s 
syndrome, they classify individuals in a similar manner as the previous AECG criteria [88] 
and we therefore have no reason to believe that implementation of the new criteria would 
have a significant impact on results presented in this thesis. Nevertheless, in Paper I and II, 
we used the presence of anti-La/SSB autoantibodies for stratification of the cohorts. Although 
the presence of anti-La/SSB autoantibodies alone does not seem to be a valuable marker for 
classifying patients [89], we would like to underline the value of considering the presence of 
these autoantibodies for patient stratification, which will be discussed later in the thesis.  
The clinical and immunological heterogeneity of Sjögren’s syndrome has posed great 
challenges both when dissecting the immunopathology of the disease, and in clinical trials 
aimed at identifying effective therapies. In efforts to reduce variation introduced by such 
heterogeneity, we in Paper III and V-VII chose to mainly study patients positive for anti-
Ro/SSA autoantibodies. Whereas this may reduce inter-individual variability between 
patients, a consequence is that the observations may not be applicable to all patients with 
Sjögren’s syndrome. However, with the emergence of more personalized medicine, we 
believe that studies of selected patient subgroups are of great importance. 
3.2 GENE EXPRESSION ANALYSIS 
Nanostring technology was applied for gene expression analysis in Papers III, V, and VI. 
This method utilizes fluorescently labelled probes for direct quantification of mRNA 
molecules, thus eliminating the need of generating cDNA by reverse transcription and 
subsequent amplification steps. The process is largely automated on the nCounter system, 
thus further reducing variability that may otherwise be induced during sample processing. 
However, Nanostring gene expression analysis is limited to exploration of pre-defined genes 
lists, in our case the Human Immunology CodeSet v2 entailing 594 genes. We chose this 
method partly due to its lower cost and availability in our research environment, but also 
because of its need for very small amounts of RNA input (50 ng total RNA). We had opted 
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for studying sorted cell populations and were consequently limited by amounts of purified 
total RNA, mainly due to low cell counts in some patient samples. It would have been 
advantageous with a less biased approach to gene expression analysis in the form of either 
microarrays or RNA sequencing. Indeed, in Paper VI we employed whole transcriptomic 
analysis by RNA sequencing and were able to detect >4000 differentially expressed genes in 
CD19+ B cells comparing patients and controls.   
3.3 PROTEIN MEASUREMENTS 
To measure protein levels in serum and plasma, we used Olink proximity extension assay 
(PEA) technology which is a multiplexed assay determining levels of pre-selected protein 
panels [170]. The PEA method utilizes dual antibody recognition of each target meaning that 
two antibodies coupled to DNA oligonucleotides need to bind epitopes in close proximity, 
and thereafter hybridize, for a target to be detected. Advantages of this method are therefore 
the high specificity in detection of targets, the possibility of creating multiplexed assays with 
high throughput, as well as the small sample volume needed (one µl of serum or plasma). We 
selected the Immuno-Oncology panel encompassing 92 proteins for our studies since it 
contained the largest number of proteins in our interest. Although many proteins were found 
to be differentially abundant in the circulation comparing patients and controls, the 
understanding of proteomic differences is limited due to the pre-selection of proteins. For this 
reason, we did not perform any pathway enrichment analyses on the protein data, since the 
limited number of proteins that are already selected for their relevance in immunology would 
skew such an analysis toward detection of immunological pathways. 
When designing the studies resulting in Paper III and IV, we selected time points 
optimal for measuring serological responses (day 0, 28 and 90) and induced gene expression 
(day 0 and day 1) following vaccination. However, we also aimed to determine perturbations 
in the plasma proteome. Although we could detect significant differential changes for three 
proteins comparing the control and patient group (Paper III, Figure 2B), we realized that 
twenty-four hours may be a too short interval for optimal studies of changes in the circulating 
proteome. In light of this, we did not perform a corresponding proteome analysis in Paper IV 
encompassing both day 0 and day 1, but instead focused our efforts on understanding the 
proteomic profile prior to vaccination and how it associated with serological responses. 
3.4 QUANTIFICATION OF INTERFERON SYSTEM ACTIVITY 
The large number of different type I IFN molecules together with their low concentrations 
during normal physiological conditions make their direct measurements challenging [1]. For 
this reason, expression of ISGs is often used as a proxy for quantification of interferon system 
activation. The expression of selected panels of such genes can be normalized against a 
control group and summed up into a so called “IFN score”, calculated as a sum of Z-scores. 
In our studies, we have used a previously published formula [171] for generation of several 




Although methods for direct quantification of type I IFNs have been developed, such as 
the SIMOA assay for IFN-a [172], no such assay suitable for routine clinical assessment of 
IFN system activity is available. In Paper V, two novel methods for measuring IFN system 
activity are presented in the protein IFN (pIFN) score and the DNA methylation (DNAm) 
IFN score. However, the pIFN score is based on PEA technology and the DNAm IFN score 
on DNA methylation analysis on an Illumina HM450K BeadChip. Both these methods are 
costly and difficult to implement in clinical practice, wherefore we suggest these scores to be 






4 RESULTS AND DISCUSSION 
In this section, the papers included in this thesis will not be discussed in the order indicated 
by their Roman numerals. Instead, to achieve better logic, the papers will be discussed in a 
manner starting with exogenous factors, thereafter endogenous factors, and lastly perturbed 
endogenous factors. 
4.1 ENVIRONMENTAL FACTORS IN SJÖGREN’S SYNDROME 
At the initiation of the work leading up to this thesis, few studies had investigated potential 
environmental risk factors for Sjögren’s syndrome. Moreover, most of the available studies 
had been performed in prevalent cases and analyzed current exposure, not specifically 
considering exposures occurring before diagnosis. Logically, risk factors will exert their 
effect before or during initial stages of the disease development, preceding established 
diagnosis. For a disease like Sjögren’s syndrome, which typically has an insidious onset 
spanning several years, this presents considerable challenges. Partly owing to non-specific 
symptoms such as fatigue, dryness, and arthralgia, the diagnosis may be delayed both due to 
diagnostic challenges for the physician as well as the patient’s hesitance to seek medical care. 
Indeed, in the cohort studied in Paper II, the patient-reported average delay between 
symptom onset and diagnosis was 6.2 years. A further challenge when assessing possible 
environmental risk factors for Sjögren’s syndrome is that dryness of mucosal tissues may act 
to change behavior due to discomfort, and that the disease itself may impair innate mucosal 
barrier functions. In addition, it is plausible that different environmental factors could be 
important for diverse and heterogenous sub-phenotypes of the disease with separate 
symptomatic, biologic, and genetic characteristics. In all, risk factor studies in Sjögren’s 
syndrome pose particular challenges which must be taken into special consideration. 
Identification of environmental risk factors depends on high-quality exposure data and 
the commonly used retrospective case-control studies have an inherent risk for recall bias and 
misclassification errors. Furthermore, it is important to keep in mind that whereas 
observational studies are critical for identifying potential environmental risk factors, they 
cannot prove causation. Confirmation of results from observational studies in multiple 
populations strengthens possible causation, but only experimental studies determining how 
agents break immunological tolerance can provide final proof. Interactions between specific 
genotypes and risk factors [173, 174], variability in disease phenotypes, critical time frames 
of exposure, and hormonal changes during the lifespan are factors further adding to the 
complexity of epidemiological risk factor studies. 
In our efforts to assess potential environmental risk factors for Sjögren’s syndrome, we 
chose to focus on cigarette smoking (Paper I) since smoking is an established risk factor for 
several autoimmune diseases such as RA [54] and MS [48], and infections (Paper II) since 
microbial triggers have long been suspected to be important in the pathogenesis [107]. 
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4.1.1 Detailing smoking patterns preceding diagnosis 
To assess the influence of smoking on the development of Sjögren’s syndrome, we 
performed a questionnaire-based case-control study in our national Swedish patient cohort 
and matched controls from two previous studies in RA [54, 175]. A total of n=815 patients 
were invited to participate in the study, out of which n=606 patients (74%) responded to the 
questionnaire, making our study the largest questionnaire-based risk factor study performed 
in Sjögren’s syndrome. During subsequent matching of up to n=15 controls per patient, some 
patients could not be successfully matched and thus the final number of patients included in 
the analyses was n=530. Reassuringly, demographics of these patients were similar to those 
of the total invited cohort (Paper I, Table 1). The index year was defined as the year of 
diagnosis for patients, and the year of responding to the questionnaire for controls. Odds 
ratios (ORs) were estimated by logistic regression conditioned on the matching by age at 
index date, calendar time at index date, sex, and area of residency. 
4.1.1.1 Lower frequencies of smoking among cases 
We observed lower rates of ever smoking (37% vs 44%) and current smoking (7% vs 16%) 
comparing patients and controls, which resulted in ORs of 0.67 (95% CI 0.55 – 0.81) and 
0.37 (95% CI 0.26 – 0.53), respectively.  
The observation of a lower frequency of current smoking is consistent with previous 
studies in prevalent cases [176-178], and could intuitively be explained by a lower likelihood 
of patients to smoke due to ocular, oral, and respiratory irritation caused by tobacco smoke. 
Another, but perhaps less likely, explanation for this observation would be that smoking 
decreases the likelihood of disease development. Cigarette smoke has indeed been described 
to have extensive immunomodulatory properties [179, 180]. Notably, one study employing 
the 2002 AECG criteria found lower frequency of focal sialadenitis and lower mean focus 
scores in minor salivary gland biopsies from currently smoking compared to non-smoking 
patients [177], and one older study using the previous Copenhagen classification criteria 
[181] showed similar results with significantly lower rates of abnormal focus scores in 
currently smoking compared to never smoking patients [182]. Such observations could 
however also be explained by a higher likelihood for patients with lower focus scores and less 
inflammation to continue smoking, possibly owing to milder disease symptoms.  
Only one previous study has considered exposure to smoking prior to diagnosis and in 
that study, individuals who would later develop Sjögren’s syndrome were less probable to be 
current smokers, but more likely to be former smokers, thus suggesting former smoking as a 
risk factor for disease [58]. In our study, estimates of former smoking were not significant 
and displayed consistent trends of ORs below 1, wherefore we have no indications that 
smoking is a risk factors for development of Sjögren’s syndrome. This inconsistency could 
relate to differences in study design and the fact that in the study by Olsson et al., the 
exposure data had been collected in a health survey with a median time of 8.2 years prior to 
diagnosis.  
Stratification of patients according to anti-Ro/SSA and La/SSB serology resulted in 
similar OR estimates for ever and current smoking in the autoantibody positive and negative 
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patient groups (Paper I, Table 2). I found this result surprising considering the genetic [82] 
and clinical [83] differences between these patient subgroups. However, this similarity could 
be interpreted as support for a hypothesis that early, and perhaps unrecognized, disease 
symptoms of dryness decrease the probability of smoking among the patient group as a 
whole. 
4.1.1.2 Exposure to smoking over time 
To better comprehend exposure to smoking over time, we estimated period prevalence of 
smoking in 10-year strata and depicted the smoking patterns in graphs (Paper I, Figure 1). 
The graphical visualization of smoking patterns preceding diagnosis led to the major finding 
of our study, namely, that smoking patterns were similar comparing cases and controls up 
until approximately 35 years before diagnosis, and that smoking thereafter declined in cases 
compared to the controls. To quantify these observations, we calculated likelihoods to stop 
smoking, which statistically supported a decline in exposure in patients relative to controls. 
Likewise, in these analyses, no large differences could be observed based on stratification by 
autoantibody status among the cases. 
To my knowledge, our study is the first to describe smoking exposure patterns that 
precede diagnosis of Sjögren’s syndrome at this level of detail. The interpretation of these 
results is however challenging and should be approached with care. Why does the prevalence 
of smoking decline already 30-40 years prior to diagnosis? Is the explanation that those who 
continue smoking are better protected against development of Sjögren’s syndrome? Or is it 
rather so, that individuals who develop disease have early and unrecognized symptoms 
causing them to stop smoking already many years before diagnosis? Our study cannot 
provide definitive answers to these questions. On one hand, it is possible that cigarette smoke 
could act to diminish inflammation and that smoking discontinuation thus could trigger 
disease. For example, it is widely acknowledged that current smoking confers protection 
against ulcerative colitis (UC) [183]. In fact, heavy smokers present with milder disease 
compared to light smokers [184], and smoking patients are less likely to require 
corticosteroid treatment compared to non-smokers [185]. Intriguingly, UC, like Sjögren’s 
syndrome is a disease affecting mucosal tissues, which could suggest shared influence of 
smoking on similar pathological processes between the two diseases. On the other hand, 
smoking has been identified as a risk factor for the immunologically related diseases SLE and 
RA [54, 186], wherefore it is difficult to mechanistically explain how the autoimmune 
processes would drastically differ in Sjögren’s syndrome. Further explanations for our 
observations could be that some smokers attribute symptoms of dryness to their smoking, but 
may in fact have Sjögren’s syndrome, and therefore remain undiagnosed. Alternatively, that 
physicians are less prone to investigate and diagnose symptoms of dryness in smoking 
individuals. 
4.1.1.3 Smoking and risk-associated HLA 
We, for the first time, had the possibility to assess potential interactions between risk-
associated HLA haplotypes and smoking. This is of special relevance since smoking has been 
shown to interact with risk-associated HLA in seropositive RA [187] and MS [48]. We 
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selected HLA-DRB1*03 and HLA-DRB1*15 for our analyses, since these alleles have been 
associated with Sjögren’s syndrome and production of autoantibodies [82, 94]. We also 
included HLA-DRB1*01/04/10 to mark shared epitope based on its interaction with smoking 
in RA [187]. Analysis of HLA haplotype frequencies in our cohort confirmed previous 
observations of the associations between HLA-DRB1*03 and Sjögren’s syndrome (Paper I, 
Supplementary table 3). However, our analysis did not reveal any significant interactions 
between smoking and the investigated HLAs, which could perhaps be expected since 
smoking had not been identified as a risk factor for Sjögren’s syndrome. 
4.1.1.4 Complexities of the role of smoking in Sjögren’s syndrome 
A methodological limitation of our study is that the cases answered the questionnaire at a 
median time of 10 years after diagnosis, which could cause differences in recall bias between 
cases and controls. It would have been ideal to perform the study on incident cases, but we 
did not have that possibility at the time. Furthermore, recall bias may increase the longer back 
in time that exposure is analyzed. Nevertheless, this error would presumably not differ 
between cases and controls. We defined the year of diagnosis as the index date, however, it 
would be interesting and perhaps preferential to define the year of symptom onset as the 
index date. Such data were available for a considerable fraction of the cases in our study but 
changing the index date to the year of self-reported symptom onset did not have a large 
impact on the observations, wherefore those data were not included in the final manuscript.  
Strengths of our study are the relatively high number of patients in comparison with 
previous studies, and that all cases were classified according to the AECG criteria [86]. 
Furthermore, we were able to stratify patients not only based on autoantibodies, but also 
based on risk-associated HLA, which had not previously been done. 
In all, we show that smoking does not seem to increase the risk of developing Sjögren’s 
syndrome and that patients compared to controls are more likely to stop smoking already 
several decades before diagnosis. The data may be interpreted in various ways and we cannot 
exclude the possibility that smoking confers protection. However, the observations could also 
be explained by behavioral changes due to symptoms of dryness appearing long before 
diagnosis. Future studies should be performed on incident cases, with detailed exposure data 
and careful patient stratification based on clinical symptoms, disease manifestations, 
serology, as well as genetics. 
4.1.2 Infections as a conceivable trigger 
As reviewed in the introduction of this thesis, viral infections constitute the main 
environmental factor discussed in the context of Sjögren’s syndrome. The hypothesis of viral 
triggers partly stems from observations of increased activity of the anti-viral type I IFN 
system in a majority of patients [115], and from the involvement of TLR receptors 
recognizing endosomal nucleic acids [112]. Although previous studies have indicated higher 
frequencies of antibodies targeting viral proteins from e.g. EBV [188, 189] and human T-
lymphocyte virus type 1 (HTLV-1) [190], these studies are all performed in prevalent cases 
and therefore do not indicate causation. To better comprehend possible connections between 
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previous infections and development of Sjögren’s syndrome, we therefore utilized the unique 
possibilities of the Swedish national health care registers. 
In Paper II, we used a well-characterized national cohort consisting of n=945 patients 
fulfilling the 2002 AEGC criteria [86]. Each case was matched by sex, age, and region of 
residency through the Swedish Total Population Register to n=10 control individuals from the 
general population (n=9048). Data on infections were then linked to each individual through 
the National Patient Registry, which includes data on hospitalizations since 1987 and 
outpatient care since 2001 but not patient visits to general practitioners. In an effort to reduce 
reverse causation, infections occurring within one year before Sjögren’s syndrome diagnosis 
were not considered in the analyses. Odds ratios were estimated by conditional logistic 
regression. 
4.1.2.1 Infections and disease development 
Exposure to infections was higher in cases compared to controls (21.4% vs 12.9%), resulting 
in an OR of 1.9 (95% CI 1.6-2.3). Similarly to Paper I, we performed analyses stratifying 
cases based on autoantibody positivity and found that the association between a history of 
infections and anti-Ro/SSA and anti-Ro/SSB positive disease was stronger (OR 2.7, 95% CI 
2.0-3.5) compared that of autoantibody negative disease (OR 1.9, 95% CI 1.4-2.7). Although 
the latter estimate supports a relationship between infection also with autoantibody negative 
disease, it is interesting that the association with anti-Ro/SSA and La/SSB autoantibody 
positive disease is stronger, which would indicate a mechanism whereby autoantibody 
production can be triggered by infections. This model fits well with observations made in 
Paper III where we could observe that titers of anti-Ro52 autoantibodies increased in 
untreated patients following viral antigen exposure, an observation that was also made in a 
previous study following adjuvanted anti-H1N1 influenza vaccination [191]. Indeed, transient 
autoantibody production has been described even in healthy persons following infection with 
e.g. hepatitis B and C, parvovirus B19, EBV, and human immunodeficiency virus [192]. 
Notably, patients with autoantibodies against Ro/SSA and La/SSB are more frequently IFN 
signature positive [115], younger at diagnosis (Paper II, Table 1), and more often carry risk-
associated HLA (Paper I, Supplementary figure 3), which indicates that discrete autoimmune 
processes are at play in these individuals.  
4.1.2.2 Routes of infection 
To investigate various routes of infection, we specifically assessed infections in the 
gastrointestinal, respiratory, cutaneous, and urogenital systems since these sites represent 
main barriers for pathogen entry. We found that infections of the skin, respiratory tract, and 
urogenital system associated with development of Sjögren’s syndrome. Interestingly, 
observations at these sites also displayed higher odds ratios in the autoantibody positive 
patient group, while only respiratory infections were found to associate with autoantibody 
negative disease (Paper II, Table 2). Gastrointestinal infections were not found to associate 
with disease. Considering the results in Paper I, it would be interesting to assess the 
association between respiratory infections and disease in the context of smoking, since 
smoking will predispose for such infections. However, data on smoking were unfortunately 
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not available at the time of the study. Indeed, smokers contract more bacterial and viral 
respiratory infections, including more and worse colds as well as influenzas, and also have 
increased risk of bacterial pneumonia [193]. Keeping in mind that smoking exposure was 
lower in patients compared to controls in Paper I, other causes of the higher rate of 
respiratory infections in patients need to be considered, including genetic and mucosal factors 
associated with Sjögren’s syndrome. Undoubtedly, the mucosal dryness associated with the 
disease could be an important factor for increased susceptibility for infections and could 
constitute a cause of reverse causality in our study. However, even when excluding infections 
occurring during seven years prior to diagnosis in the analysis, the associations with 
respiratory infections still persisted (Paper II, Figure 2). In future studies, we therefore aim 
to study infections as a risk factor in the context of both smoking and genetic factors. 
4.1.2.3 Infections as triggers of Sjögren’s syndrome 
Our observations of an association between infections and later development of Sjögren’s 
syndrome are in accordance with a registry-based study from Denmark where n=1977 
patients had been identified by ICD codes and associations with a history of hospitalizations 
for infections was investigated [194]. In that study, the number of infections was associated 
with a dose-dependent risk of Sjögren’s syndrome, which is also in agreement with our 
observations (Paper II, Figure 1). Likewise, a small, interview-based study found increased 
rates of infections requiring hospitalization prior to diagnosis among patients diagnosed 
according to the AECG criteria compared to controls [195].  
 Limitations of our study include a lack of data on oral infections, and that we were 
unable to discriminate between viral and bacterial infections in our analyses. Strengths 
include that the patients were classified according to the AECG criteria, that we were able to 
perform analysis stratified by autoantibody status, and the contextually large number of 
patients.  
In all, our study adds to growing evidence to suggest infections as an important 
environmental factor in the pathogenesis of Sjögren’s syndrome. However, no studies have 
thus far considered potential associations with minor infections that do not require specialized 
care, and this remains an important query for future studies. 
Infections remain a main suspect as trigger of immunopathogenic mechanisms in 
Sjögren’s syndrome. While efforts have been made to identify specific infections that could 
initiate or propagate disease, no single microbial agent has been convincingly identified and it 
seems plausible that several different infections may act to stimulate the initiation of 
autoimmune processes (reviewed by myself and colleagues in [66]). In order to learn more 
about such microbial triggers, it is of great interest to study serological and cellular responses 
during infection in patients with an immune system prone to autoimmunity. With this in 
mind, we designed the studies which resulted in Paper III and IV, in which we monitor 
immunologic perturbations following exposure of viral antigens in untreated and HCQ-
treated patients with Sjögren’s syndrome and SLE. 
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4.2 CELLULAR AND TRANSCRIPTIONAL PROFILING IN SJÖGREN’S 
SYNDROME 
Alterations in several parts of the cellular immune system are evident in the exocrine tissue 
pathology of Sjögren’s syndrome, with disturbances in T cells, B cells, and glandular cells. 
Early lymphocytic infiltrates in salivary glands are characterized by a high proportion of T 
cells, around 80%, and to a lesser extent B cells, although the proportion of B cells increases 
in advanced lesions [196]. The ratio of CD4+/CD8+ T cells is highly biased toward CD4+ 
cells, which display an activated phenotype and produce pro-inflammatory cytokines [197]. 
Moreover, epithelial cells have been suggested as important mediators of pathology with 
expression of immune-competent molecules [76], and with the capability of mediating 
activation and differentiation of T cells [198]. 
The direct involvement of B cells in the immunopathology of Sjögren’s syndrome is 
apparent from frequent observations of hypergammaglobulinemia, production of 
autoantibodies and studies showing deranged B cell subpopulations [199]. Furthermore, 
formation of ectopic GCs can be observed in minor salivary glands of patients and is 
associated with an increased risk of lymphomagenesis, primarily non-Hodgkin lymphomas of 
B-cell type [102]. The chemokine CXCL13 and its corresponding receptor CXCR5 are of 
central importance for the recruitment and organization of B and T cells in the GCs. Indeed, 
the importance of the CXCR5-CXCL13 axis has been demonstrated in murine models where 
CXCR5 deficient mice miss various types of peripheral lymph nodes and the majority of 
Peyer’s patches [200]. Correspondingly, overexpression of CXCL13 in mice results in 
augmented formation of ectopic lymphoid tissue [201]. In addition, the involvement of 
CXCR5 in the pathogenesis of Sjögren’s syndrome was further implied in the largest genetic 
association study to date, in which gene polymorphisms close to the CXCR5 locus associated 
with disease [94]. 
With the aim to better understand mechanisms underlying cellular dysregulation in 
Sjögren’s syndrome, we performed whole transcriptome sequencing of peripheral CD19+ B 
cells (Paper VI) and explored abnormalities of the CXCR5-CXCL13 axis (Paper VII). 
4.2.1 The transcriptome of peripheral B cells 
To identify differences in gene expression, we performed RNA sequencing of peripheral 
CD19+ B cells from n=12 patients and n=20 healthy controls. At the time, our study was the 
first to employ whole transcriptome sequencing on this cell type. For validation of our 
findings, we employed Nanostring gene expression analysis in a replication cohort consisting 
of n=16 patients and n=17 controls. All included patients were diagnosed according to the 
AECG criteria [86]. In order to reduce variability in the cohort, we chose to only include 
female patients positive for anti-Ro/SSA autoantibodies. Peripheral B cells were isolated 




4.2.1.1 RNA sequencing of peripheral B cells 
In the RNA sequencing dataset, 4047 autosomal genes were found to be differentially 
regulated, out of which 1826 had upregulated and 2221 had downregulated expression levels 
comparing patients and controls (Paper VI, Supplementary table S2 and S3).  
A prominent representation of genes related to IFN responses was noted among the 
genes with higher expression in patients, both including genes associated with type I IFN 
responses such as MX1, IFI27, IFI44L, IFI44, OAS1, and OAS2 but also genes indicative of 
responses to type II IFN such as GBP1, GBP, and IFI16. A subsequent gene enrichment 
analysis could confirm the significant enrichment of genes related to IFN signaling (Paper 
VI, Supplementary Table S6). We thus, for the first time, provided evidence of an IFN 
signature in peripheral CD19+ B cells, which has thereafter been confirmed by RNA 
sequencing in two recent studies [202, 203]. Of note, prior to our study, a type I IFN 
signature in CD19+IgD+ naïve B cells from untreated patients with Sjögren’s syndrome had 
been described [191]. A type I IFN signature had previously also been detected in salivary 
gland tissue, whole blood, and in various peripheral blood mononuclear cells [81, 113, 114, 
204, 205]. To compare levels of type I IFN-induced gene expression in patients and controls, 
we calculated IFN scores from expression levels of ISGs, and found these to be higher in 
patients compared to controls (Paper VI, Supplementary figure S3).  
Among the downregulated genes, we noted several genes involved in negative 
regulation of cytokine signaling, including several members of suppressors of cytokine 
signaling (SOCS) such as SOCS1 and SOCS3, which are negative-feedback inhibitors that act 
via the JAK/STAT pathway and are important regulators of type I IFN pathway signaling. 
Other noteworthy regulators with lower expression in patients compared to controls included 
PTPN1 which dephosphorylates JAK and TYK kinases, and TNFAIP3 encoding the protein 
A20 which is a negative regulator of NF-kB signaling. Interestingly, a germline missense 
variant of the TNFAIP3 gene has been associated with lymphoma in Sjögren’s syndrome 
[206], thus further indicating the importance of this gene in B cell dysregulation.  
A specific analysis was carried out for genes on the X chromosome among patients and 
female controls, in which higher expression of TLR7, TLR8 and Bruton tyrosine kinase (BTK) 
was noted.  
4.2.1.2 Replication of gene expression data 
For validation of the results acquired by RNA sequencing in a separate cohort, we employed 
a Nanostring gene expression panel including 594 genes related to immunology. Partly due to 
limited overlap, higher expression could be confirmed for 52 genes, and lower expression for 
5 genes. Out of the upregulated and replicated genes, CX3CR1 distinguished itself by 
displaying the highest fold change. This gene encodes the fractalkine receptor, which has 
been implicated in B cell lymphomas, including marginal zone lymphomas of mucosa-
associated lymphoid tissue (MALT), i.e. the most commonly occurring lymphoma in 
Sjögren’s syndrome [207]. Its ligand, fractalkine, promotes adhesion and migration of 
inflammatory cells. High protein expression of fractalkine on ductal cells, and of the 
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fractalkine receptor on inflammatory cells in focal infiltrates, has been demonstrated in 
salivary glands from patients with Sjögren’s syndrome [208]. 
Higher expression of several genes of the tumor necrosis factor superfamily such as 
TNFSF4 encoding OX40L, TNFSF10 encoding TRAIL, TNFSF13B encoding BAFF, and 
TNFRSF17 encoding the BAFF receptor could also be validated. Of relevance, OX40L 
promotes the expansion of T follicular helper cells (Tfh) which are crucial for GC formation 
[209, 210] and a genetic polymorphism in the TNFSF4 gene has previously been associated 
with Sjögren’s syndrome [211]. Further, the higher expression of BAFF and its receptor’s 
genes fits well with previous data showing that levels of BAFF are increased at the mRNA 
and protein level in salivary glands, and as circulating protein in patients with Sjögren’s 
syndrome compared to controls, correlating with autoantibody titers and with disease activity 
[113, 119, 212-215]. Of note, BAFF expression can be induced by type I IFN [117], and an 
association between secretion of BAFF by monocytes and the IFN signature has been 
demonstrated in Sjögren’s syndrome [115]. Together, our data suggest a possible mechanism 
for ongoing B cell activation through transcriptional dysregulation of BAFF and its 
functionally related genes. 
The higher expression of TLR7 and its downstream signaling molecule IRF7 were 
replicated, and increased expression of IRF7 in circulating CD19+ B cells has subsequently 
been confirmed in two later studies [202, 203]. Other noteworthy differentially regulated 
genes included CCL5 (RANTES) and its receptor CCR1, STAT1, STAT2, and TNFSF7 also 
known as CD70. 
4.2.1.3 Gene expression in relation to DNA methylation 
Gene methylation data were available for co-analysis from a previous study, which had partly 
included the same patents. A total of 77 genes were shown to be both differentially expressed 
and differentially methylated, out of which many where ISGs. Of particular interest in the 
context of Paper VII, we could identify hypermethylation in the promotor region of CXCR5, 
which was associated with a lower gene expression in patients compared to controls. The 
lower expression of CXCR5 in B cells observed in Paper VI is in line with discoveries made 
in Paper VII, namely, that a genetic polymorphism associated with Sjögren’s syndrome 
results in lower expression of CXCR5 in CD19+ B cells. 
In all, we performed the first whole transcriptome sequencing study of peripheral B 
cells in Sjögren’s syndrome and could identify and replicate dysregulated genes participating 
in several immunological processes. At the time, we were the first to establish a type I and 
type II IFN signature in CD19+ B cells, underlining the influence of these cytokines on B cell 
functions. The ongoing immune activation detected in our study strengthens the rationale for 
drug trials of biologics targeted at B cell inhibition or depletion. Furthermore, our study 
identified distinct pathways which may be of essential importance in the pathogenesis of 
Sjögren’s syndrome and therefore could constitute targets for future therapeutic intervention. 
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4.2.2 Detailing the role of chemokine receptor CXCR5 
In 2013, Lessard et al. published the first large-scale association study performed in a 
Caucasian population, in which several genetic variants associated with Sjögren’s syndrome 
were identified [94]. In that study, polymorphisms in the q23.3 locus on chromosome 11 
close to the CXCR5 locus were identified. Intriguingly, CXCR5-CXCL13 and CXCR4-
CXCL12 have been suggested as key chemokine axes in the formation of ectopic GCs [96]. 
Thus, in Paper VII, we set out to investigate the CXCR5-CXCL13 axis in Sjögren’s 
syndrome in order to better understand the impact of the identified disease-associated 
polymorphisms of the CXCR5 locus.  
4.2.2.1 A novel eQTL effect at the CXCR5 gene locus 
To comprehend whether gene expression of CXCR5 was dependent on the genotype in 
CD19+ B cells, we performed an expression quantitative trait loci (eQTL) analysis on a 
cohort of healthy individuals originally described by Fairfax et al. [216]. Since the top-
associated SNP rs7119038 from the study by Lessard et al. was not available in the Fairfax et 
al. dataset [94], we instead used a proxy SNP rs4938573 which was in high linkage 
disequilibrium (r2>0.8) with rs7119038. The analysis revealed that the disease risk allele T 
resulted in a significantly, albeit fold-change wise moderately lower expression of CXCR5 in 
CD19+ B cells. 
4.2.2.2 Differential cell population frequencies 
To examine frequencies of T and B cell subpopulations expressing CXCR5 and to achieve 
semi-quantitative values of CXCR5 cell surface expression by measuring median 
fluorescence intensity (MFI), we performed flow cytometry experiments in a cohort of 
untreated anti-Ro/SSA positive patients and in healthy controls. We could confirm previous 
observations in the B cell compartment [199] in the form of lower frequencies of marginal 
zone (MZ) B cells and tendencies of higher naïve and lower memory B cell proportions in 
patients compared to controls. Notably, it has been hypothesized that lower frequencies of 
CD27+ memory cells in patients with Sjögren’s syndrome could result from recruitment of 
these cells to inflamed glandular tissue, or because of exaggerated differentiation into plasma 
cells [217]. Further, the soluble form of CD27 (sCD27) has been described at higher levels in 
the circulation of patients compared to controls [218], an observation which is also supported 
by our data (Paper III, Supplementary figure S4A), and sCD27 has been proposed as a 
marker of abnormal differentiation of memory B cells into plasma cells [217]. 
In the patients, frequencies of CXCR5 positive cells among total B cells were reduced 
owing to lower frequencies of CXCR5 positive memory, MZ, and CD27-IgD- double 
negative (DN) cell subsets. Moreover, CXCR5 cell surface expression measured in MFI 
exhibited a similar tendency of lower expression, which corresponds with the results of the 
eQTL analysis. For a majority of the patients, we had SNP data for rs4938573 and could thus 
relate CXCR5 surface expression to genotype. Although no patient was homozygous for C, 
patients homozygous for the risk allele T had a lower cell surface expression of CXCR5 on 
CD19+CD27+IgD- memory B cells and a tendency of lower expression in MZ and DN B 
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cells, indicating that the risk-associated genotype contributes to lower levels of CXCR5 
expression. 
In the T cell compartment, we noted lower frequencies of CXCR5 positive Th17 cells 
comparing patients and controls, however, frequencies of Tfh cells were not found to differ. 
Tfh cells assist in the differentiation of B cells into plasma cells in GCs and have previously 
been reported at higher frequencies in the circulation of patients with Sjögren’s syndrome, 
also correlating with lymphocytic infiltration of the salivary glands and with disease activity 
scores [219]. Of note, four of the patients in our study had increased levels of Tfh cells but 
these patients did not stand out in terms of clinical or histological data. Considering the fact 
that frequencies of Tfh cells previously have been associated with disease activity, one 
explanation as to why we did not note differences in frequencies of Tfh cells could be that the 
patients of our study had relatively low disease activity. 
4.2.2.3 Abundance of CXCR5+ cells in target tissue 
We hypothesized that the lower abundance of CXCR5 positive cells in the circulation might 
result from increased homing to the target organ. In line with this hypothesis, we noted higher 
levels of CXCL13 protein in the circulation of patients compared to controls. Interestingly, 
higher levels of CXCL13 in  the blood of patients with Sjögren’s syndrome has been 
associated with a history of lymphoma [220, 221]. Further, by immunohistochemical 
staining, we could detect abundant CXCL13 protein expression and higher numbers of 
CXCR5 positive cells within focal infiltrates and interstitially in salivary glands from patients 
compared to controls. 
In all, we detected lower frequencies of CXCR5 expressing B cell subsets, which also 
displayed lower cell surface expression of CXCR5 in patients compared to controls. 
Furthermore, patients had higher levels of CXCL13 in the circulation and abundant CXCL13 
protein and high numbers of CXCR5+ cells in the salivary gland tissue. Of note, a recent 
study found expression of CXCL13 to be induced by type I IFN [222], thus indicating a 
mechanism whereby high circulating levels in patients may be generated. While the lower 
CXCR5 expression on cells in patients could partly be explained by an eQTL effect caused 
by the disease-associated polymorphism, we suggest that these observations likely relate to 
increased homing of CXCR5+ cells to the target tissue. Our data thus further indicate 
dysregulation of the CXCR5-CXCL13 axis in Sjögren’s syndrome, suggesting that this 
pathway may be a candidate for therapeutic intervention. 
4.3 QUANTIFICATION OF INTERFERON SYSTEM ACTIVITY 
Although there is strong support for the involvement of type I IFNs in the immunopathology 
of systemic autoimmune diseases [223], their roles are highly complex and remain 
incompletely understood. While IFNs contribute to efficient protection against viral 
infections, chronic exposure to increased levels of type I IFNs such as in SLE and Sjögren’s 
syndrome is thought to shift the immune system toward pathological functions [223]. In fact, 
highlighting the complex properties of IFNs, around 3000 genes have been annotated as IFN 
regulated in the Interferome database [224], with functions including but not limited to anti-
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viral and bacterial defense, immune regulation, apoptosis, and cell differentiation. 
Furthermore, on one hand, type I IFNs may be used to treat MS and certain types of cancer, 
yet on the other hand, such treatment may cause development of SLE or symptoms of SLE, 
although often transiently with symptoms that usually fade when treatment is discontinued 
[45, 159, 225]. In Sjögren’s syndrome, an increased type I IFN signature has been associated 
with anti-Ro/SSA and anti-La/SSB autoantibodies, higher serum IgG titers, lower 
lymphocyte counts, and higher ESSDAI scores [115, 226-228]. 
As reviewed in the introduction to this thesis, various reasons make the direct 
measurement of type I IFNs difficult, and therefore, expression levels of ISGs are usually 
assessed to calculate mRNA-based IFN scores. Although both type I and type II IFNs have 
been implicated in the pathogenesis of Sjögren’s syndrome [226], a considerable overlap in 
their induction of ISGs complicate discrete understanding of their specific contribution to the 
immunopathology of the disease. 
4.3.1 Novel methods for quantification of interferon system activity 
Standard assessment of IFN system activity relies on RNA samples, which also need to be 
well preserved since RNA will degrade over time. However, plasma, serum, and DNA 
samples are often more available in historical cohorts and large research studies. With this in 
mind, we therefore set out to find alternative markers for IFN system activity, which resulted 
in Paper V. 
4.3.1.1 Quantification of IFN scores based on expression of ISGs 
To establish gene expression-based IFN scores to be used as reference, we measured the 
expression of ISGs by qPCR and by Nanostring technology in peripheral blood monocytes 
and B cells. As could be expected, we found high correlation between IFN scores measured 
by qPCR and by Nanostring, confirming previous observations that Nanostring may be used 
for accurate and easy quantification of IFN scores [229, 230]. In fact, Nanostring technology 
can be used directly on cell lysates, thus eliminating cumbersome steps of RNA isolation and 
amplification, which is advantageous for clinical application. Further, we could demonstrate 
correlations between mRNA-based IFN scores in simultaneously sampled monocytes and B 
cells, which had not been specifically shown in Sjögren’s syndrome before, thus indicating 
that either of these cell types may be used for assessment of type I IFN scores with similar 
results. Indeed, higher IFN scores has previously been described in many cell types and in the 
target tissue in Sjögren’s syndrome patients [81, 113, 115, 226], showing that the effect of 
type I IFNs is widespread and systemic. Induced transcription of ISGs by type I IFNs depend 
on the cell surface expression of IFNAR as well as the expression of downstream signaling 
components. In future studies in Sjögren’s syndrome, it would be interesting to determine 
whether certain cells types are more sensitive to changes in IFN levels, which could 




4.3.1.2 Establishing the pIFN score 
To establish a pIFN score, we employed PEA technology in plasma and serum using a panel 
of 92 proteins selected for their relevance in immunology. In our analysis, a combined score 
calculated from relative levels of CXCL10, CXCL9, and the soluble form om PD-1 (sPD-1) 
was found to correlate the best with the mRNA-based IFN scores. It is possible that screening 
other PEA panels or proteins would bring about other or more relevant IFN activity markers, 
but in our dataset the addition of further proteins did not improve performance of the score. 
Although the proteins used for calculation of the pIFN score had been identified based on the 
fact that their corresponding mRNA expression is type I IFN induced [224], we hesitate to 
claim that the pIFN score would be specific only for type I IFN activity, partly since both 
CXCL10 and CXCL9 are known to be induced also by IFN-g. Other studies have proposed 
soluble or cell surface bound proteins as surrogate markers of IFN system activity in systemic 
autoimmune diseases [227, 231-234], however, keeping in mind the many subtypes of type I 
IFN and that the profile of ISGs may differ between individuals, we reasoned that a pIFN 
combining levels of several proteins would be more stable than a single protein marker alone.  
To understand whether the score would perform similarly in serum as in plasma, we 
measured the pIFN score in simultaneously collected serum and plasma samples. Indeed, we 
found that pIFN scores correlated well between serum and plasma, thus further supporting its 
usefulness. The cohort used to establish the pIFN score only encompassed anti-Ro/SSA 
positive patients. Therefore, to determine pIFN score levels also in autoantibody negative 
patients, we measured serum pIFN scores in a large cohort encompassing both anti-Ro/SSA 
positive patients, and patients negative for both anti-Ro/SSA and anti-La/SSB. We found the 
pIFN score to be the highest in anti-Ro/SSA positive patients, which is in accordance with 
previous reports [115, 226], however, the score was significantly higher also in autoantibody 
negative patients compared to controls. This observation is particularly intriguing considering 
that proposed models of type I IFN production in Sjögren’s syndrome generally describe a 
mechanism through which autoantibodies form RNA-containing immune complexes which 
undergo FcgRIIa-mediated endocytosis by pDCs whereby endosomal TLRs are stimulated, 
thus resulting in production of type I IFN [112]. However, although pDCs have long been 
viewed as main producers of type I IFN in autoimmune diseases [235], this notion was 
recently challenged in a publication showing that pDC from patients with Sjögren’s 
syndrome and SLE may have lost their capacity for TLR-mediated cytokine production and 
that they have reduced telomere length, together with a transcriptional signature indicative of 
cellular stress and senescence [236]. To my knowledge, levels of type I IFN activity in 
autoantibody negative patients with Sjögren’s syndrome compared to controls has not been 
specifically studied. Unfortunately, we do not have RNA samples to generate mRNA-based 
IFN scores in the autoantibody negative patients of our cohort, and I therefore cannot assess 
whether the increased levels of the pIFN score in these patients correlates with expression of 
ISGs, or if discrete mechanisms are causing the increased levels of the proteins. 
The possibility to assess IFN system activation in serum and plasma samples enables 
new insights in historical cohort for which only such samples have been stored. This is the 
case for many older biobanks. However, the effect of storage conditions and time of storage 
on the pIFN should be evaluated in future studies.  
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4.3.1.3 Establishing the DNAm IFN score 
Based on our observations of hypomethylation of ISGs in Paper VI, we hypothesized that an 
IFN activity score similar to the pIFN score could be established based on levels of DNA 
methylation. To generate the DNAm IFN score, we assessed correlation of CpG methylation 
levels at type I IFN induced genes [224] to RNA sequencing-based mRNA scores in B cells 
from a separate cohort of patients and controls. Reassuringly, the assessment of ISG 
expression by qPCR compared to RNA sequencing has been found to yield comparable and 
consistent results [237]. We calculated the DNAm IFN score based on beta values of CpG 
sites at three genes, and the score was found to correlate well with the mRNA-based scores 
and to achieve high concordance rate (97.2%) with the mRNA-based score when classifying 
individuals as having positive or negative IFN scores. In a separate cohort, additional 
assessment of the DNAm IFN score in whole blood confirmed higher scores in anti-Ro/SSA 
positive patients compared to controls, and likewise, significantly higher scores in 
autoantibody negative patients compared to controls, which further substantiates the 
corresponding observations when employing the pIFN score. The ability to assess both 
genotype and phenotype, i.e. IFN system activation, in DNA samples opens up great 
possibilities, not least in large cohort studies such as GWAS studies for which DNA may be 
the only biologic material available for analysis.  
The ability to determine IFN scores by measurement of gene expression, protein, and 
DNA methylation levels generates new questions regarding the kinetics of the various scores. 
Indeed, DNA methylation patterns are mitotically heritable at the cellular level and are 
thought to be relatively stable over time, yet possibilities of methylation changes in response 
to external stimuli are still maintained [238]. Consequently, it could possibly be so, that the 
DNAm IFN score is more stable over time, while mRNA and protein-based scores are more 
dynamic and subject to faster changes. This line of thought would suggest that the DNAm 
IFN score could be better at accurately classifying patients and controls, whereas the pIFN 
score may constitute a better biomarker e.g., of responses to treatment. In our study, we did 
not have the possibility to examine such kinetics of the different scores, which is something I 
would like to assess in futures studies. I am especially interested in the temporal 
circumstances regarding hypomethylation of ISGs and whether a high DNAm IFN score 
perhaps could identify individuals at increased risk of developing systemic autoimmunity. 
However, studies indicating that gene expression precedes hypomethylation would speak 
against such a scenario [239]. 
Limitations of our study relate to the fact that we did not have the possibility to assess 
the pIFN and DNAm IFN scores in the same samples nor in other infectious or rheumatic 
diseases, which would have been of added value.  
4.3.1.4 Assessing IFN system activity in systemic autoimmune diseases 
The complex involvement of type I IFNs in systemic autoimmune disease and their 
widespread effects in the body are still being untangled. However, in a recent phase III trial of 
the anti-IFN receptor monoclonal antibody anifrolumab, a higher frequency of response 
measured by British Isles Lupus Assessment Group-based Composite Lupus Assessment 
(BICLA) at week 52 was noted in the treated compared to the placebo group (47.8% versus 
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31.5%), thus validating the type I IFN pathway as an effective treatment target [160]. As 
intended, the drug rapidly neutralized the IFN signature in the actively treated patient group. 
However, further adding to the complexity of the IFN system in Sjögren’s syndrome, a recent 
phase II trial of RSLV-132, an RNase Fc fusion protein, revealed that treatment with this 
drug counterintuitively resulted in upregulation instead of downregulation of IFN-inducible 
genes, while at the same time improving symptoms of severe fatigue [240]. The potential of 
targeting IFN signaling in the treatment of Sjögren’s syndrome is still attractive considering 
the encouraging evidence for efficacy of anifrolumab in SLE [160]. In future trials of such 
drugs, various measures of IFN system activity could be of central importance, for which the 
methods presented in Paper V can be considered.  
Bearing in mind the potential differences in kinetics of the various IFN scores, it would 
be very interesting to assess all of these scores simultaneously e.g., in the clinical trials 
evaluating anifrolumab. Does the blocking of the type I IFN receptor effect the DNA 
methylation profile at IFN inducible genes? If so, when does this change occur and how long 
does it persist after discontinuation of treatment? Such a study could provide further insights 
into the dysregulation of type I IFN signaling in systemic autoimmunity. 
Together, our study provides new tools for the assessment of IFN activity, which are 
especially valuable in instances where RNA samples are not available. The methods we 
present may not only be of value in large studies where only plasma/serum and DNA has 
been collected, but their employment could potentially lead to a better understanding the 
kinetics of IFN dysregulation in systemic autoimmunity. 
4.4 MICROBIAL ANTIGEN EXPOSURE IN SYSTEMIC AUTOIMMUNITY 
The hypothesis that infections may trigger or propagate systemic autoimmunity is long-
standing, and we have presented additional evidence to support this model in Paper II of this 
thesis. However, efforts to identify specific infectious agents causing development of 
Sjögren’s syndrome, or the immunologically related disease SLE, have not been very 
successful [66, 241]. An explanation for this could be that several different infectious agents 
have the potential of provoking autoimmune processes in genetically predisposed individuals. 
Hypothetically, infections could act in a non-specific manner to propagate and amplify 
otherwise quiescent deficiencies in central or peripheral tolerance mechanisms, which may 
already be ongoing in susceptible individuals. However, to detect such defective pathways in 
humans would require the in vivo study of immune mechanisms during infections, which is 
logistically challenging when it comes to spontaneously occurring infections, and ethically 
problematic if infections would need to be induced. In our efforts to better understand 
immunological perturbations during encounters with microbial antigens in the context of 
autoimmunity, we therefore monitored responses following vaccinations, which are safe and 
recommended for patients with rheumatic diseases [169]. We specifically studied patients 
with no or little treatment in order to understand processes transpiring in an immune system 
unmanipulated by intense treatment. 
Prior to this thesis, Brauner et al. had reported that adjuvanted anti-H1N1 vaccination in 
untreated patients with Sjögren’s syndrome resulted in higher vaccine-specific antibody titers 
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compared to controls, together with increased autoantibody titers in the patients [191]. 
However, the vaccine used in that study contained the adjuvant squalene and it remained 
unknown whether non-adjuvanted vaccination would result in similar observations. 
Furthermore, initial innate responses which may underlie production of higher antibody 
levels had not been assessed.  
Therefore, to identify differences in serological and cellular responses following non-
adjuvanted viral antigen exposure, we monitored untreated and HCQ-treated female patients 
with Sjögren’s syndrome and SLE, and age-matched healthy controls during non-adjuvanted 
trivalent seasonal influenza vaccination in Paper III and Paper IV. 
4.4.1 Augmented responses against viral antigens 
A main finding of our studies was that untreated patients with Sjögren’s syndrome and 
patients with SLE receiving no or light treatment responded to viral antigens with higher 
vaccine-specific antibody titers compared to healthy controls. In SLE, patients receiving 
HCQ with or without low-dose prednisolone developed similar titers as untreated patients, 
whereas the HCQ-treated group of patients with Sjögren’s syndrome had a non-significant 
tendency to respond with lower titers compared to untreated patients, yet still with non-
significantly higher titers than controls. 
Of note, we aimed to assess an overall B cell reactivity in our studies and therefore 
primarily focused on measuring all antibodies targeted against the viral antigens, and not only 
neutralizing antibodies, which are commonly measured when assessing vaccine responses in 
terms of seroconversion and seroprotection rates. Furthermore, our statistical assessment of 
antibody production focused on the relative change, and not the absolute levels, in antibody 
titers. Whereas a previous study, as mentioned above, supports our observations in Sjögren’s 
syndrome [191], studies in SLE have mostly reported lower frequencies of protective 
antibodies in patients compared to controls [168, 242, 243], while untreated and HCQ-treated 
SLE patients seem to attain similar seroprotection frequencies as controls [168, 244]. 
However, importantly, these studies have generally assessed neutralizing antibodies and not, 
as in our studies, all antibodies mounted against the foreign antigens. Consequently, our 
results could be interpreted as patients producing an overall larger number of antibodies 
targeting the vaccine, whereas the effects of neutralizing antibodies may not differ compared 
to controls. Nevertheless, in Paper III, neutralizing antibodies against hemagglutinin 
measured by hemagglutination inhibition assay against the H3N2 strain were indeed higher in 
patients compared to controls, but there were no differences for the other strains. 
A possible explanation for the higher antibody production could be that autoimmune 
patients, due to defects in tolerance mechanisms, have a larger pool of naïve B cells with a 
higher number of potential reactivities. Another possible explanation could be that due to 
ubiquitous autoimmune processes, patients have a larger amount of lymphoid tissue e.g., GCs 
and will therefore mount amplified antibody responses. Indeed, patients with Sjögren’s 
syndrome and SLE have high levels of the GC-associated chemokine CXCL13 in the 
circulation [221, 245, 246], and frequently form ectopic GCs in which high numbers of Tfh 
cells critical for B cell antibody responses are present. An additional explanation could be 
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that B cells in patients are in a state of general hyperactivity caused by chronic stimulation 
from type I IFNs and associated high levels of the B cell simulating cytokine BAFF. 
Moreover, another important factor is the possible association between disease risk-
associated HLA haplotypes and development of higher antibody responses. Ideally, the 
healthy control group could be genetically matched to the patient group in terms of risk-allele 
carriage in order to account for this factor, which we were unfortunately not able to do in our 
studies. In fact, various HLA class II haplotypes have been associated with differences in 
serological responses against influenza antigens [247-249]. Therefore, future studies 
dissecting responsiveness to viral antigens in patients with systemic autoimmunity should 
take genetic factors such as HLA into consideration. 
In order to reduce inter-individual variability and to avoid interference by immune-
modulatory drugs, we only studied patients with Sjögren’s syndrome positive for anti-
Ro/SSA autoantibodies, and patients with SLE receiving no or light treatment i.e., with low-
active disease. Therefore, our results may not be generally applicable to the patient groups as 
a whole. However, in SLE, we believe that studying this group of patients gives insight into 
processes that would also be true for patients with higher disease activity, had they not been 
treated, although this remains to be demonstrated. 
4.4.1.1 Autoantibody titers following vaccination 
Bystander activation of autoreactive B cells has been proposed as a mechanism whereby 
infections could trigger autoimmunity. In a previous study, increased autoantibody titers 
following vaccination were observed in untreated patients with Sjögren’s syndrome [191]. 
Therefore, to assess potential non-specific activation of B cells in our studies, we measured 
autoantibody titers in patients. In Sjögren’s syndrome, anti-Ro52 autoantibodies were found 
to increase in untreated but not in HCQ-treated patients. However, in patients with SLE, who 
present with a broader range of autoantibodies, titers of several autoantibodies were analyzed 
yet none were found to be affected in neither untreated nor in patients on light treatment. This 
may be related to the power of the study since there were relatively few patients in each 
group when stratified according to autoantibody specificities. The increase in anti-Ro52 
autoantibodies in Sjögren's syndrome patients are in line with the study by Brauner et al., 
however, the relative change in Paper III was less than that observed for a squalene-
adjuvanted vaccine [191]. In SLE, previous studies present diverging data, with some 
indicating increased titers of autoantibodies following influenza vaccination [250, 251], and 
others not [252, 253]. 
It is interesting that treatment with HCQ seemed to counteract production of 
autoantibodies in patients with Sjögren’s syndrome, an observation which corresponds to the 
non-significant tendency for lower production of vaccine-specific antibodies in those patients. 
Hydroxychloroquine partly acts by inhibiting endosomal TLR signaling [254, 255], and 
treatment with HCQ has been reported to lower the expression of ISGs in patients with 
Sjögren’s syndrome [256]. Correspondingly, naïve B cells from patients treated with HCQ 
have a lower propensity to differentiate into antibody secreting plasmablasts upon endosomal 
TLR ligation [191]. Although the largest clinical trial to date did not demonstrate efficacy for 
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HCQ treatment in terms of decreasing symptoms in Sjögren’s syndrome [127], our data 
suggest potential protective effects in terms of suppressed autoantibody production. 
4.4.1.2 Vaccinations are well-tolerated 
In our studies, vaccination against influenza was not associated with any exacerbations of 
underlying disease and patient-reported symptoms remained unchanged both in patients with 
Sjögren’s syndrome and SLE during a follow-up period of 90 days. Although our studies 
were not designed to assess safety, these observations confirm previous reports that 
vaccination does not aggravate clinical symptoms of rheumatic diseases [257]. While there 
have been case reports of disease development or flares of Sjögren’s syndrome and SLE 
following vaccination, literature reviews have not corroborated such observations [165, 257]. 
Rather, it has been concluded that the advantages of vaccination in rheumatic patients by far 
outweigh potential risks. Together, our data support the current recommendations by EULAR 
i.e., that non-adjuvanted influenza vaccination appears safe and should be encouraged for 
patients with Sjögren’s syndrome and SLE. 
In conclusion, augmented antibody responses toward viral antigens in the two diseases 
suggest a state of hyperreactivity in B cells and further signifies viral infections as an 
important environmental risk factor for systemic autoimmunity. Furthermore, our data for 
Sjögren’s syndrome indicate a mechanism whereby viral antigens trigger bystander activation 
of autoreactive cells, which is in concordance with our observations in Paper II, in which a 
history of infections more closely associated with development of autoantibody positive 
disease. We also conclude that non-adjuvanted, compared to squalene adjuvanted, vaccines 
may be preferable when vaccinating untreated patients with Sjögren’s syndrome. Finally, our 
data support that influenza vaccination does not cause increased autoantibody production in 
patients with low-active SLE.  
4.4.2 A relationship between type I IFN system and antibody responses 
Monocytes are important effector cells at the interface of innate and adaptive immunity. In 
Sjögren’s syndrome compared to controls, a higher monocyte expression of type I ISGs 
together with higher expression of BAFF, and TLR7 and its downstream signaling molecules 
had previously been reported [115, 205].  
To better understand which factors that may underlie augmented serological responses, 
we therefore performed gene expression analysis in CD14+ monocytes from peripheral blood. 
In Paper III, the pre-vaccination transcriptional signature assessed by Nanostring was 
dominated by a type I IFN signature, and a higher type I IFN system activation was found to 
associate with a higher vaccine-specific antibody response at day 28. Based on these 
observations, we opted for a qPCR-based IFN score in Paper IV and observed a 
corresponding relationship between IFN score and vaccine-specific antibody titers that 
developed in patients with SLE. Although we had not observed any changes in autoantibody 
titers in patients with SLE after vaccination, we found that the number of autoantibody 
specificities was highly positively correlated with the IFN score. 
 
 41 
In all, we observed that higher pre-vaccination type I IFN scores in monocytes 
associate with augmented production of vaccine-specific antibodies, thus supporting 
proposed models in which high type I IFN activation promotes B cell activation and antibody 
production in systemic autoimmunity [120]. Our data are in line with experiments showing 
that pre-stimulation of naïve B cells from healthy subjects with IFN-α enhances plasmablast 
differentiation and class switch [191]. Interestingly, it was recently reported that a gene 
signature composed of ten IFN-regulated genes was useful for predicting both antibody 
responses to influenza vaccination in healthy subjects as well as reflecting the magnitude of 
plasmablast-associated disease flares in patients with SLE [258, 259]. Although increased 
IFN scores have been found to associate with higher disease activity in both Sjögren’s 
syndrome and in SLE [171, 227, 228], the observations made in healthy subjects therefore 
suggest that it may in fact be type I IFN, and not disease activity itself, which associates with 
higher antibody production. 
4.4.2.1 The proteome in relation to vaccination  
To detect perturbations in the blood proteome following viral antigen exposure, we measured 
the levels of 92 proteins in plasma before and 24 hours after vaccination (Paper III). In our 
analysis, we specifically aimed to identify proteins displaying significantly different 
responses comparing patients and controls and found differential regulation of the levels of 
the monocyte-attracting chemokine CCL7. Also, in line with the observations of increase in 
type I IFN scores in both patients and controls (Paper III, Figure 3C), the IFN-induced 
proteins CXCL10 and CXCL9 were identified in the analysis, however, these proteins 
displayed similar regulation in both patients and controls. CCL7 is involved in trafficking of 
monocytes, thus suggesting differences in the recruitment of monocytes following 
vaccination, possibly to the site of injection. Although the proteome screen was 
comprehensive, we detected differential regulation of relatively few proteins, which likely 
relates to the fact that a later time point would have been better for assessment of changes in 
the proteome, since production of such proteins generally could be expected to take more 
than 24 hours. With this in mind, we focused our resources on only analyzing the proteome 
prior to vaccination in Paper IV. 
To assess whether blood proteins could be useful in predicting antibody responses to 
vaccination, we analyzed pre-vaccination protein levels in relation to vaccine-specific 
antibody titers at one month. The proteins with the strongest correlation were sPD-1 in 
Sjögren’s syndrome and CCL3 in SLE, which notably are both type I IFN regulated proteins 
at the mRNA level [224]. Indeed, sPD-1 was used to calculate the pIFN score in Paper V and 
CCL3 has previously been suggested as a marker of type I IFN activation in SLE [260]. 
Further supporting a central role for PD-1 in the pathogenesis of autoimmune disease are 
reports of patients developing manifestations of systemic autoimmune disease following 
checkpoint inhibition of the PD-1/PD-L1 pathway during treatment for cancer [19]. Although 
the top proteins correlating with antibody titers at day 28 differed between the two diseases, 
the enrichment of IFN-regulated proteins was striking in both studies.  
Of note, many of the proteins detected at significantly differential levels comparing 
patients and controls (Paper III, Supplementary figure S4A; Paper IV, Table 2) are 
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generally thought of as membrane-bound proteins. The fact that we detect these proteins in 
the circulation suggests that they have either been shed from the membrane, or that they have 
been actively secreted. The soluble form of these proteins may have properties to inhibit or 
intensify their signaling pathways. For example, sPD-1 has been proposed to block the PD-
1/PD-Ls pathway, thereby promoting T cell responses [261]. Therefore, the detection of 
soluble forms of classical membrane-bound proteins requires further studies in order to 
understand their function and possible contribution to autoimmune pathogenesis. 
Together, we observe markers of type I IFN activation also at the protein level and their 
association with higher production of antibodies after viral antigen exposure further imply 
type I IFNs to be of central importance in generation of augmented humoral responses. 
Several differentially abundant proteins identified in our blood proteome screens, which have 
not previously been reported, warrant closer investigation and replication in separate cohorts. 
4.4.3 Differences in early transcriptional events suggest roles for NF-kB 
Whereas previous studies have detailed steady-state transcriptional profiles of various cell 
types in Sjögren’s syndrome, no studies prior to this thesis had specifically examined 
transcriptional responses following exposure to microbial antigens.  
To comprehend potential differences in transcriptional changes induced by viral 
antigens comparing patients and controls, we analyzed changes in gene expression from 
before and 24 hours after vaccination in monocytes. We found that the most significant gene 
with a simultaneous relative increase in Sjögren’s syndrome patients compared to controls 
was the IKBKG gene encoding the protein NF-kB-essential modulator (NEMO). Moreover, 
we observed that the induced expression of NEMO, as well as of a summarized NF-kB 
activation score, correlated with vaccine-specific IgG titers at day 28.  
The NEMO protein is a part of the IKK complex which acts to activate NF-kB gene 
transcription by phosphorylation of the inhibitory IkBa (Figure 1). While this protein has not 
previously been studied in Sjögren’s syndrome, human deficiencies of NEMO have been 
associated with the disease incontinentia pigmenti [262], as well as other immunodeficiencies 
[263], and mutations have been shown to result in defect NF-kB activation and impaired 
responses to TLR agonists [264, 265]. Intriguingly, and in line with our data, monocytes in 
Sjögren’s syndrome were previously shown to express lower levels of IkBa compared to 
controls [266], and increased gene expression of the NF-kB transcription factors NFKB1 and 
NFKB2 [267]. In addition, identification of genome wide association with the gene TNFAIP3 
interacting protein 1 (TNIP1), which encodes an A20-bining protein [94], further suggests 
that dysregulated activation of NF-kB signaling may be important in the 
immunopathogenesis of Sjögren’s syndrome.  
Altogether, our data indicate that dysregulated activation of NF-kB in monocytes may, 
at least in part, underlie higher serological responses in patients. The suggestive importance 
of NEMO in the pathogenesis of Sjögren’s syndrome should be studied further.  
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4.4.4 Potential impact of IFN-targeted treatment 
To conclude, in our studies of Sjögren’s syndrome and SLE, we observed strong indications 
that type I IFNs exert influence on serological responses to viral antigens, which is in line 
with previous in vitro experiments showing that type I IFN primes naïve B cells for higher 
plasmablast differentiation and immunoglobulin production [191]. Our data fit well in 
proposed models where type I IFN leads to production of the B cell stimulating cytokine 
BAFF, thereby causing increased B cell differentiation and antibody production. 
Furthermore, our data imply the importance of dysregulated NF-kB signaling in monocytes 
in the generation of higher serological responses in Sjögren’s syndrome. Altogether, our data 
add to the understanding of immune reactions toward microbial antigens in autoimmune 
immune systems and imply infections as an important environmental risk factor for 
autoimmune disease. 
A major challenge, however, in identifying relevant pathways in these diseases are the 
widespread effects of type I IFNs, which have major influence both on gene transcription as 
well as on blood proteome signatures, thus making it difficult to detect other dysregulated 
pathways which could be of key importance. To tackle this, it will be especially interesting to 
study responses to microbial antigens in patients who receive treatment with anti-IFN 
targeted drugs such as anifrolumab, through which the type I IFN signature is rapidly 
normalized [160]. Would such treatment lower antibody responses in patients to the level of 
controls? Would it perhaps significantly impair vaccination responses? Indeed, vaccination 
leads to type I IFN responses also in healthy subjects (Paper III, Figure 3C), which are likely 
important for generation of adequate serological responses. Upon normalization of the type I 
IFN signature by anifrolumab in patients, other important pathways may emerge more clearly 
when they are not masked by otherwise ubiquitously present type I IFN signature. Future 




5 CONCLUDING REMARKS 
In this thesis, we employed different approaches and methodologies to better characterize 
exogenous and endogenous factors of importance in the immunopathology of Sjögren’s 
syndrome and the related autoimmune disease SLE. 
We observed that previous and current cigarette smoking was less frequent among 
Sjögren’s syndrome cases compared to controls. This was related to a decline in smoking 
exposure among cases starting approximately 35 years prior to diagnosis, which was in part 
explained by a higher probability of smoking discontinuation among cases compared to 
controls. We therefore conclude that smoking does not appear to be a risk factor for 
development of Sjögren’s syndrome. However, since disease associated dryness may 
influence behavior, we aim to more closely define exposure to smoking in incident cases in 
the future. Moreover, we identified that a history of infections is a risk factor for development 
of Sjögren’s syndrome, with higher risk estimates for anti-Ro/SSA and anti-La/SSB positive 
disease. Thus, our data add to growing evidence indicating infections as an important 
environmental risk factor for Sjögren’s syndrome. Future studies should assess the influence 
also of minor infections not requiring specialized care, and risk factor studies should in 
general employ careful patient stratification based on clinical symptoms, disease 
manifestations, autoantibody status, as well as genetics.  
We observed that percentages of CXCR5+ B cells in the circulation and their surface 
expression of CXCR5 is lower in patients with Sjögren’s syndrome compared to controls. At 
the same time, the chemokine ligand CXCL13 is increased in plasma and high numbers of 
CXCR5+ cells are present in salivary glands. This could be explained by increased homing of 
B cells with high cell surface expression of CXCR5 to the autoimmune target tissue. 
Furthermore, we found extensive differences in the transcriptome of circulating CD19+ B 
cells comparing patients with Sjögren’s syndrome and controls, including prominent type I 
and type II IFN signatures in patients. Our results add to the understanding of B cell 
dysregulation and identify potential therapeutic targets warranting further study. 
We present two novel methods which can be employed for quantification of IFN 
system activation using serum/plasma or DNA samples. These methods are especially 
valuable in studies where RNA samples have not been collected. An interesting question for 
future studies would be the dynamics of the IFN signature at the mRNA, protein, and DNA 
methylation level, especially considering the emerging anti-IFN therapies. 
In our studies, untreated patients with Sjögren’s syndrome and patients with SLE 
receiving no or light treatment responded to viral antigen exposure with higher vaccine-
specific antibody titers compared to controls, thus mirroring a B cell hyperreactivity. A 
higher serological response was related to increased markers of activation of the type I IFN 
system prior to vaccination, and in Sjögren’s syndrome a higher response was also linked to 
dysregulated NF-kB signaling in monocytes. These observations further elucidate 
mechanisms through which microbial triggers affect autoimmunity-prone immune systems. 
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Taken together, the data presented in this thesis expand the current understanding of the 
autoimmune pathogenesis of primary Sjögren’s syndrome. A summary of the factors studied 
in this thesis are presented in the figure below (Figure 5). 
 
 
Figure 5. Summary of factors studied in this thesis. The figure was created using images from 
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